Tabula Rasa HealthCare (TRHC) 10-Q 5 Aug 22 2022 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2022	Jul. 29, 2022
Cover [Abstract]
Document Type	10-Q
Document Quarterly Report	true
Document Period End Date	Jun. 30, 2022
Document Transition Report	false
Entity File Number	001-37888
Entity Registrant Name	Tabula Rasa HealthCare, Inc.
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	46-5726437
Entity Address, Address Line One	228 Strawbridge Drive, Suite 100
Entity Address, City or Town	Moorestown
Entity Address, State or Province	NJ
Entity Address, Postal Zip Code	08057
City Area Code	866
Local Phone Number	648 - 2767
Title of 12(b) Security	Common Stock
Trading Symbol	TRHC
Security Exchange Name	NASDAQ
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes
Entity Filer Category	Large Accelerated Filer
Entity Small Business	false
Entity Emerging Growth Company	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		26,251,035
Entity Central Index Key	0001651561
Current Fiscal Year End Date	--12-31
Document Fiscal Year Focus	2022
Document Fiscal Period Focus	Q2
Amendment Flag	false

CONSOLIDATED BALANCE SHEETS

CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets:
Cash	$ 26,522	$ 9,395
Restricted cash	7,062	6,038
Accounts receivable, net of allowance of $103 and $110, respectively	20,324	21,405
Inventories	5,798	5,444
Prepaid expenses	3,534	3,812
Client claims receivable	14,419	11,257
Other current assets	25,021	18,033
Current assets of discontinued operations	163,624	14,511
Total current assets	266,304	89,895
Property and equipment, net	10,126	11,778
Operating lease right-of-use assets	14,656	16,323
Software development costs, net	31,275	29,254
Goodwill	115,323	115,323
Intangible assets, net	41,970	45,358
Other assets	4,814	3,929
Noncurrent assets of discontinued operations		187,558
Total assets	484,468	499,418
Current liabilities:
Line of credit	57,200
Current operating lease liabilities	3,038	3,275
Accounts payable	15,802	8,870
Client claims payable	8,751	8,398
Accrued expenses and other liabilities	50,179	40,997
Current liabilities of discontinued operations	19,158	12,380
Total current liabilities	154,128	73,920
Line of credit		29,500
Long-term debt, net of discount of $3,646 and $5,701, respectively	231,626	319,299
Long-term debt - related party, net of discount of $1,391 and $0, respectively	88,337
Noncurrent operating lease liabilities	14,034	15,792
Deferred income tax liability, net	1,034	1,402
Other long-term liabilities	1,992	176
Noncurrent liabilities of discontinued operations		3,573
Total liabilities	491,151	443,662
Commitments and contingencies (Note 15)
Stockholders' equity (deficit):
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at June 30, 2022 and December 31, 2021
Common stock, $0.0001 par value; 100,000,000 shares authorized, 26,799,516 and 26,036,236 shares issued and 26,260,181 and 25,666,434 shares outstanding at June 30, 2022 and December 31, 2021, respectively	3	3
Treasury stock, at cost; 539,335 and 369,802 shares at June 30, 2022 and December 31, 2021, respectively	(4,292)	(4,292)
Additional paid-in capital	335,756	320,392
Accumulated deficit	(338,150)	(260,347)
Total stockholders' equity (deficit)	(6,683)	55,756
Total liabilities and stockholders' equity (deficit)	$ 484,468	$ 499,418

CONSOLIDATED BALANCE SHEETS (pa

CONSOLIDATED BALANCE SHEETS (parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
CONSOLIDATED BALANCE SHEETS
Allowance for accounts receivable	$ 103	$ 110
Long-term debt, discount	3,646	5,701
Long-term debt - related party, discount	$ 1,391	$ 0
Preferred stock, par value (in dollars per share)	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	10,000,000	10,000,000
Preferred stock, shares issued	0	0
Preferred stock, shares outstanding	0	0
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	100,000,000	100,000,000
Common stock, shares issued	26,799,516	26,036,236
Common stock, shares outstanding	26,260,181	25,666,434
Treasury stock (in shares)	539,335	369,802

CONSOLIDATED STATEMENTS OF OPER

CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Revenue:
Total revenue	$ 72,597	$ 64,297	$ 139,707	$ 123,075
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	56,631	47,620	109,352	91,599
Operating expenses:
Research and development	3,243	4,311	7,208	7,370
Sales and marketing	2,172	2,539	4,821	5,506
General and administrative	15,150	16,652	31,028	31,332
Long-lived asset impairment charge			4,062
Depreciation and amortization	5,489	4,980	11,231	9,781
Total operating expenses	26,054	28,482	58,350	53,989
Loss from operations	(10,088)	(11,805)	(27,995)	(22,513)
Interest expense, net	2,444	2,182	4,713	4,729
Loss from continuing operations before income taxes	(12,532)	(13,987)	(32,708)	(27,242)
Income tax expense	159	81	375	202
Net loss from continuing operations	(12,691)	(14,068)	(33,083)	(27,444)
Net loss from discontinued operations, net of tax	(36,919)	(7,013)	(44,720)	(13,129)
Net loss	$ (49,610)	$ (21,081)	$ (77,803)	$ (40,573)
Net loss per share:
Net loss per share from continuing operations, basic (in dollars per share)	$ (0.53)	$ (0.60)	$ (1.38)	$ (1.19)
Net loss per share from discontinued operations, basic (in dollars per share)	(1.54)	(0.31)	(1.87)	(0.56)
Total net loss per share, basic (in dollars per share)	(2.07)	(0.91)	(3.25)	(1.75)
Net loss per share from continuing operations, diluted (in dollars per share)	(0.53)	(0.60)	(1.38)	(1.19)
Net loss per share from discontinued operations, diluted (in dollars per share)	(1.54)	(0.31)	(1.87)	(0.56)
Total net loss per share, diluted (in dollars per share)	$ (2.07)	$ (0.91)	$ (3.25)	$ (1.75)
Weighted average common shares outstanding:
Weighted average common shares outstanding, basic (in shares)	23,959,726	23,268,131	23,913,050	23,140,043
Weighted average common shares outstanding, diluted (in shares)	23,959,726	23,268,131	23,913,050	23,140,043
Product
Revenue:
Total revenue	$ 55,892	$ 46,858	$ 106,865	$ 88,700
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	43,384	35,064	82,936	66,421
Service
Revenue:
Total revenue	16,705	17,439	32,842	34,375
Cost of revenue, exclusive of depreciation and amortization shown below:
Total cost of revenue, exclusive of depreciation and amortization	$ 13,247	$ 12,556	$ 26,416	$ 25,178

CONSOLIDATED STATEMENTS OF STOC

CONSOLIDATED STATEMENTS OF STOCKHOLDERS' EQUITY (DEFICIT) - USD ($) $ in Thousands	Common Stock	Treasury Stock	Additional Paid-in Capital Cumulative Effect, Period of Adoption, Adjustment	Additional Paid-in Capital	Accumulated Deficit Cumulative Effect, Period of Adoption, Adjustment	Accumulated Deficit	Cumulative Effect, Period of Adoption, Adjustment	Total
Balance at beginning of period at Dec. 31, 2020	$ 2	$ (4,018)	$ (74,850)	$ 352,445	$ (1,392)	$ (179,900)	$ (76,242)	$ 168,529
Balance at beginning of period (in shares) at Dec. 31, 2020	24,222,674
Balance at beginning of period, treasury stock (in shares) at Dec. 31, 2020		(217,778)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock awards (in shares)	1,416
Issuance of restricted stock (in shares)	629,088
Forfeitures of restricted shares (in shares)		(12,880)
Exercise of stock options, net of shares withheld		$ (274)		2,501				2,227
Exercise of stock options, net of shares withheld (in shares)	224,503	(6,218)
Stock-based compensation expense				8,602				8,602
Net loss						(19,492)		(19,492)
Balance at end of period at Mar. 31, 2021	$ 2	$ (4,292)		288,698		(200,784)		83,624
Balance at end of period (in shares) at Mar. 31, 2021	25,077,681
Balance at end of period, treasury stock (in shares) at Mar. 31, 2021		(236,876)
Balance at beginning of period at Dec. 31, 2020	$ 2	$ (4,018)	$ (74,850)	352,445	$ (1,392)	(179,900)	$ (76,242)	168,529
Balance at beginning of period (in shares) at Dec. 31, 2020	24,222,674
Balance at beginning of period, treasury stock (in shares) at Dec. 31, 2020		(217,778)
Increase (Decrease) in Stockholders' Equity
Net loss								(40,573)
Balance at end of period at Jun. 30, 2021	$ 2	$ (4,292)		301,932		(221,865)		75,777
Balance at end of period (in shares) at Jun. 30, 2021	25,282,675
Balance at end of period, treasury stock (in shares) at Jun. 30, 2021		(259,789)
Balance at beginning of period at Mar. 31, 2021	$ 2	$ (4,292)		288,698		(200,784)		83,624
Balance at beginning of period (in shares) at Mar. 31, 2021	25,077,681
Balance at beginning of period, treasury stock (in shares) at Mar. 31, 2021		(236,876)
Increase (Decrease) in Stockholders' Equity
Issuance of restricted stock (in shares)	120,598
Forfeitures of restricted shares (in shares)		(22,913)
Exercise of stock options, net of shares withheld				885				885
Exercise of stock options, net of shares withheld (in shares)	84,396
Stock-based compensation expense				12,349				12,349
Net loss						(21,081)		(21,081)
Balance at end of period at Jun. 30, 2021	$ 2	$ (4,292)		301,932		(221,865)		75,777
Balance at end of period (in shares) at Jun. 30, 2021	25,282,675
Balance at end of period, treasury stock (in shares) at Jun. 30, 2021		(259,789)
Balance at beginning of period at Dec. 31, 2021	$ 3	$ (4,292)		320,392		(260,347)		$ 55,756
Balance at beginning of period (in shares) at Dec. 31, 2021	26,036,236
Balance at beginning of period, treasury stock (in shares) at Dec. 31, 2021		(369,802)						(369,802)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock awards (in shares)	16,471
Issuance of restricted stock (in shares)	297,434
Forfeitures of restricted shares (in shares)		(138,882)
Exercise of stock options, net of shares withheld				60				$ 60
Exercise of stock options, net of shares withheld (in shares)	11,646
Stock-based compensation expense				8,609				8,609
Net loss						(28,193)		(28,193)
Balance at end of period at Mar. 31, 2022	$ 3	$ (4,292)		329,061		(288,540)		36,232
Balance at end of period (in shares) at Mar. 31, 2022	26,361,787
Balance at end of period, treasury stock (in shares) at Mar. 31, 2022		(508,684)
Balance at beginning of period at Dec. 31, 2021	$ 3	$ (4,292)		320,392		(260,347)		$ 55,756
Balance at beginning of period (in shares) at Dec. 31, 2021	26,036,236
Balance at beginning of period, treasury stock (in shares) at Dec. 31, 2021		(369,802)						(369,802)
Increase (Decrease) in Stockholders' Equity
Net loss								$ (77,803)
Balance at end of period at Jun. 30, 2022	$ 3	$ (4,292)		335,756		(338,150)		$ (6,683)
Balance at end of period (in shares) at Jun. 30, 2022	26,799,516
Balance at end of period, treasury stock (in shares) at Jun. 30, 2022		(539,335)						(539,335)
Balance at beginning of period at Mar. 31, 2022	$ 3	$ (4,292)		329,061		(288,540)		$ 36,232
Balance at beginning of period (in shares) at Mar. 31, 2022	26,361,787
Balance at beginning of period, treasury stock (in shares) at Mar. 31, 2022		(508,684)
Increase (Decrease) in Stockholders' Equity
Issuance of common stock awards (in shares)	12,262
Issuance of restricted stock (in shares)	424,540
Forfeitures of restricted shares (in shares)		(30,542)
Exercise of stock options, net of shares withheld				3				3
Exercise of stock options, net of shares withheld (in shares)	927	(109)
Stock-based compensation expense				6,692				6,692
Net loss						(49,610)		(49,610)
Balance at end of period at Jun. 30, 2022	$ 3	$ (4,292)		$ 335,756		$ (338,150)		$ (6,683)
Balance at end of period (in shares) at Jun. 30, 2022	26,799,516
Balance at end of period, treasury stock (in shares) at Jun. 30, 2022		(539,335)						(539,335)

CONSOLIDATED STATEMENTS OF CASH

CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Cash flows from operating activities:
Net loss	$ (77,803)	$ (40,573)
Adjustments to reconcile net loss to net cash provided by operating activities:
Depreciation and amortization	18,562	23,244
Amortization of deferred financing costs and debt discount	939	1,172
Deferred taxes	(368)	263
Stock-based compensation	15,301	20,951
Acquisition-related contingent consideration paid		(67)
Impairment charges	40,510
Other noncash items	(54)	7
Changes in operating assets and liabilities:
Accounts receivable, net	2,979	(2,737)
Inventories	(354)	(605)
Prepaid expenses and other current assets	(7,916)	(3,811)
Client claims receivables	(3,162)	207
Other assets	(769)	(2,546)
Accounts payable	9,295	(926)
Accrued expenses and other liabilities	9,188	7,646
Client claims payables	353	(1,332)
Other long-term liabilities	2,139	7
Net cash provided by operating activities	8,840	900
Cash flows from investing activities:
Purchases of property and equipment	(471)	(970)
Software development costs	(17,870)	(14,011)
Net cash used in investing activities	(18,341)	(14,981)
Cash flows from financing activities:
Proceeds from exercise of stock options	60	3,082
Payments for debt financing costs	(350)	(8)
Borrowings on line of credit	27,700	12,500
Payment of acquisition-related notes payable		(13,000)
Payments of acquisition-related contingent consideration		(99)
Repayments of long-term debt and finance leases		(4)
Net cash provided by financing activities	27,410	2,471
Net increase (decrease) in cash and restricted cash	17,909	(11,610)
Cash and restricted cash, beginning of period	15,706	28,532
Cash and restricted cash, end of period	33,615	16,922
Supplemental disclosure of cash flow information:
Purchases of property and equipment and software development included in accounts payable and accrued expenses	2,693	131
Cash paid for interest	3,882	3,398
Cash paid for taxes	137	47
Interest costs capitalized to software development costs	$ 202	$ 134

CONSOLIDATED STATEMENTS OF CA_2

CONSOLIDATED STATEMENTS OF CASH FLOWS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2022	Jun. 30, 2021
Reconciliation of cash and restricted cash:
Cash	$ 26,522	$ 11,421
Restricted cash	7,062	4,657
Cash from discontinued operations	31	844
Total cash and restricted cash	$ 33,615	$ 16,922

Nature of Business

Nature of Business	6 Months Ended
	Jun. 30, 2022
Nature of Business
Nature of Business	1. Nature of Business ​ Tabula Rasa HealthCare, Inc. (the “Company”) is a healthcare technology company advancing the safe use of medications by creating solutions designed to empower pharmacists, providers, and patients to optimize medication regimens. The Company’s advanced proprietary technology, MedWise®, identifies causes of and risks for medication-related problems, including adverse drug events, so healthcare professionals can minimize harm and reduce medication-related risks. The Company’s software and services help improve patient outcomes and lower healthcare costs through reduced hospitalizations, emergency department visits, and healthcare utilization. The Company serves a number of different organizations within the healthcare industry, including health plans, pharmacies, hospital sites, and at-risk provider groups, the majority of which are organizations with Programs of All-Inclusive Care for the Elderly (“PACE”). ​

Basis of Presentation, Summary

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements	6 Months Ended
	Jun. 30, 2022
Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements
Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements	2. Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements ​ (a) Basis of Presentation ​ The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the Company’s interim consolidated financial position for the periods indicated. The interim results for the three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2022 (the “2021 Form 10-K”). ​ Except as described below, there have been no material changes to the Company’s significant accounting policies described in the 2021 Form 10-K that have a material impact on the Company’s accompanying unaudited consolidated financial statements and related notes. ​ (b) Assets and Liabilities Held for Sale and Discontinued Operations ​ A long-lived asset (or disposal group) is classified as held for sale if its carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable within a year. A long-lived asset (or disposal group) classified as held for sale is initially measured at the lower of its carrying amount or fair value less costs to sell. An impairment loss is recognized for any initial or subsequent write-down of the long-lived asset (or disposal group) to fair value less costs to sell. A gain or loss not previously recognized by the date of the sale of the long-lived asset (or disposal group) is recognized at the date of derecognition. ​ Long-lived assets (including those that are part of a disposal group) are not depreciated or amortized while they are classified as held for sale. Long-lived assets classified as held for sale and the assets of a disposal group classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet. ​ Unless otherwise noted, amounts and disclosures throughout the notes to the unaudited consolidated financial statements relate to the Company’s continuing operations. ​ Additional details surrounding the Company’s assets and liabilities held for sale and discontinued operations are included in Note 3. ​ (c) Cloud Computing Arrangements ​ Costs to implement cloud computing arrangements that are hosted by third-party vendors are capitalized when incurred during the application development phase. Capitalized implementation costs are amortized on a straight-line basis over the reasonably certain term of the hosting arrangement, beginning when the service is ready for its intended use. As of June 30, 2022 and December 31, 2021, capitalized implementation costs of $1,045 and $747, respectively, were included in prepaid expenses, and $842 and $0, respectively, were included in other assets on the Company’s consolidated balance sheets. Accumulated amortization for these arrangements was $503 and $398 as of June 30, 2022 and December 31, 2021, respectively. Amortization expense for the three months ended June 30, 2022 and 2021, was $52 and $53, respectively. Amortization expense for the six months ended June 30, 2022 and 2021, was $105 and $103, respectively. ​ (d) Vendor Financing Arrangements ​ On February 24, 2022, the Company expanded its existing relationship with a third-party service provider for business process outsourcing and technology services for its third-party administration services and electronic health records solutions. As a result, the third-party provider hired approximately 180 employees from the Company, hired to fill existing open positions and will augment with additional resources to meet client demand. The agreement term is seven years and includes total estimated fees of $115,300. ​ The arrangement includes extended payment terms for cloud computing implementation costs, internally developed software support, and business process support. In order to determine the present value of the commitment, the Company used an imputed interest rate of 9.5%, which is reflective of its estimated uncollateralized borrowing rate. As of June 30, 2022, the outstanding principal balance of the financing arrangement was $2,537 with an unamortized discount of $600, and was included in accrued expenses and other liabilities and other long-term liabilities on the Company’s consolidated balance sheet. Imputed interest expense from the arrangement was $30 and $36 for the three and six months ended June 30, 2022, respectively. ​ (e) Concentrations of Credit Risk ​ The Company’s medication fulfillment services clients are sponsors of the federal Medicare Part D plan (prescription drug coverage plan) and, therefore, subject to the payment regulations established by the Centers for Medicare & Medicaid Services (“CMS”). Under CMS guidelines, Medicare Part D sponsors are required to remit payment for claims within 14 ​ The Company’s clients also include health plans, pharmacies, and other healthcare providers. Credit associated with these accounts is extended based upon management’s evaluation of creditworthiness and is monitored on an on-going basis. ​ As of June 30, 2022 and December 31, 2021, no clients represented more than 10% of net accounts receivable. ​ One client accounted for 16% and 13% of total revenue for the three months ended June 30, 2022 and 2021, respectively, and 17% and 14% of total revenue for the six months ended June 30, 2022 and 2021, respectively. ​ (f) Recent Accounting Pronouncements In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities from acquired contracts using the revenue recognition guidance under ASC Topic 606 (Revenue from Contracts with Customers) in order to align the recognition of a contract liability with the definition of performance obligation. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. ASU 2021-08 is effective for financial statements issued for fiscal years beginning after December 15, 2022; early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on the Company’s consolidated financial statements.

Discontinued Operations

Discontinued Operations	6 Months Ended
	Jun. 30, 2022
Discontinued Operations
Discontinued Operations	3. Discontinued Operations ​ ​ In February 2022, the Company announced plans to evaluate non-core assets, refocus its corporate strategy, and increase stockholder value, and the Company commenced a plan to sell the DoseMe business, which the Company acquired in January 2019. In March 2022, the Company completed its evaluation of additional divestiture opportunities and commenced plans to sell the SinfoníaRx and PrescribeWellness businesses, which were acquired in September 2017 and March 2019, respectively. ​ On June 18, 2022 (the “Signing Date”), the Company and Tabula Rasa HealthCare Group, Inc., a wholly-owned subsidiary of the Company (the “Seller”), entered into an Asset Purchase Agreement (the “PW Purchase Agreement”), by and among the Company, Seller, and Transaction Data Systems, Inc. (“TDS”), pursuant to which Seller agreed to sell to TDS its unincorporated PrescribeWellness business division (the “PrescribeWellness Business”), the assets, properties, and rights that are primarily used or held for use in connection with the PrescribeWellness Business, and the KD Assets (as defined below). As consideration, TDS agreed to pay to Seller up to $140,000 in cash, of which $125,000 was to be paid upon consummation of the sale, subject to certain adjustments related to the net working capital of the PrescribeWellness Business, subject to certain customary post-closing adjustments. The additional $15,000 was contingent consideration that may be paid to Seller based upon the PrescribeWellness Business’s achievement of certain performance-based metrics during the fiscal years ending December 31, 2023 and 2024. ​ On the Signing Date and as a condition to TDS’s entry into the PW Purchase Agreement, Seller also entered into an asset purchase agreement (the “KD Purchase Agreement”) with karmadata, Inc., a Delaware corporation (“KD”), pursuant to which Seller agreed to purchase all of KD’s rights, title, and interests in and to certain intellectual property of KD that has historically been licensed to Seller, all intellectual property owned by KD that was developed or improved pursuant to that certain IP Development Agreement, by and between Seller and KD, dated as of December 1, 2016, as amended, and all authorization rights and claims or causes of action with respect to the foregoing (collectively, the “KD Assets”). ​ The foregoing descriptions of the PW Purchase Agreement and the KD Purchase Agreements are qualified in their entirety by reference to the terms of such agreements, which are included as Exhibits 10.3 and 10.4 to this Quarterly Report on Form 10-Q. ​ As discussed in Note 18, on August 1, 2022, the Company completed the sale of the PrescribeWellness Business and the acquisition of the KD Assets. ​ The Company considers the sale of the DoseMe and SinfoníaRx businesses to be highly probable within one year. ​ At June 30, 2022, the DoseMe, SinfoníaRx, and PrescribeWellness businesses comprised the majority of the Company’s MedWise HealthCare segment. The Company’s sale of PrescribeWellness, and plan of sale with respect to DoseMe and SinfoníaRx, represents a strategic business shift having a significant effect on the Company’s operations and financial results. As a result, the Company determined that these businesses met such requirements to be classified as held for sale and discontinued operations as of March 31, 2022 and continue to meet the requirements as of June 30, 2022. Accordingly, unless otherwise indicated, the accompanying consolidated financial statements have been recast for all periods presented to reflect the assets, liabilities, revenue, and expenses related to these businesses as discontinued operations. ​ During the three and six months ended June 30, 2022, as a result of the Company’s intention to sell the aforementioned businesses, the Company prepared an impairment test on the related net assets held for sale. Using a market approach to determine fair value, the Company concluded that the carrying values of the net assets held for sale for the PrescribeWellness, SinfoníaRx, and DoseMe businesses did not exceed their fair values, less costs to sell. As a result, the Company recorded goodwill impairment charges of $17,532 related to the PrescribeWellness and SinfoníaRx businesses and $18,076 of impairment charges on the net assets held for sale related to the PrescribeWellness, SinfoníaRx, and DoseMe businesses for the three months ended June 30, 2022. For the six months ended June 30, 2022, the Company recorded goodwill impairment charges of $18,272 and impairment charges on the net assets held for sale of $18,176 related to the PrescribeWellness, SinfoníaRx, and DoseMe businesses. ​ The following table s ummarizes the results of operations of the businesses, which are included in loss from discontinued operations, net of tax in the consolidated statements of operations for the three and six months ended June 30, 2022 and 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Six Months Ended ​ June 30, June 30, ​ 2022 2021 2022 2021 Revenue $ 16,961 ​ $ 18,012 ​ $ 33,456 ​ $ 35,914 Cost of revenue, exclusive of depreciation and amortization ​ 10,197 ​ ​ 9,643 ​ ​ 19,942 ​ ​ 19,691 Operating expenses ​ 8,761 ​ ​ 15,330 ​ ​ 22,354 ​ ​ 29,222 Impairment charges ​ 35,608 ​ ​ — ​ ​ 36,448 ​ ​ — Loss from discontinued operations before income taxes ​ (37,605) ​ ​ (6,961) ​ ​ (45,288) ​ ​ (12,999) Income tax (benefit) expense ​ (686) ​ ​ 52 ​ ​ (568) ​ ​ 130 Net loss from discontinued operations, net of tax $ (36,919) ​ $ (7,013) ​ $ (44,720) ​ $ (13,129) ​ The following table summarizes the current and noncurrent assets and liabilities classified as discontinued operations on the consolidated balance sheets as of June 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2022 2021 Cash $ 31 ​ $ 273 Accounts receivable, net ​ 10,748 ​ ​ 12,646 Prepaid expenses and other assets ​ 2,940 ​ ​ 1,592 Property and equipment, net ​ 1,707 ​ ​ — Operating lease right-of-use assets ​ 4,984 ​ ​ — Software development costs, net ​ 20,012 ​ ​ — Goodwill ​ 37,240 ​ ​ — Intangible assets, net ​ 104,138 ​ ​ — Impairment of carrying value ​ (18,176) ​ ​ — Total current assets of discontinued operations $ 163,624 ​ $ 14,511 ​ ​ ​ ​ ​ ​ Property and equipment, net $ — ​ $ 1,897 Operating lease right-of-use assets ​ — ​ ​ 4,730 Software development costs, net ​ — ​ ​ 15,940 Goodwill ​ — ​ ​ 55,512 Intangible assets, net ​ — ​ ​ 109,292 Other assets ​ — ​ ​ 187 Total noncurrent assets of discontinued operations $ — ​ $ 187,558 ​ ​ ​ ​ ​ ​ Operating lease liabilities $ 4,785 ​ $ 1,413 Accounts payable ​ 6,671 ​ ​ 4,308 Accrued expenses and other liabilities ​ 7,702 ​ ​ 6,659 Total current liabilities of discontinued operations $ 19,158 ​ $ 12,380 ​ ​ ​ ​ ​ ​ Noncurrent operating lease liabilities ​ — ​ $ 3,438 Other long-term liabilities ​ — ​ ​ 135 Total noncurrent liabilities of discontinued operations $ — ​ $ 3,573 The following table summarizes the significant operating non-cash items and investing activities of discontinued operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ June 30, ​ 2022 2021 Depreciation and amortization ​ $ 7,331 ​ $ 13,463 Impairment charges ​ ​ 36,448 ​ ​ — Stock-based compensation ​ ​ 2,506 ​ ​ 3,752 Purchases of property and equipment ​ ​ (59) ​ ​ (230) Software development costs ​ ​ (6,006) ​ ​ (4,445) ​

Revenue

Revenue	6 Months Ended
	Jun. 30, 2022
Revenue.
Revenue	4. Revenue ​ The Company generates the majority of its revenue from its CareVention HealthCare segment. ​ Client contracts generally have a term of one 0 ​ The Company does not disclose the amount of variable consideration that the Company expects to recognize in future periods as the variable consideration in the Company’s contracts is allocated entirely to a wholly unsatisfied performance obligation or to a wholly unsatisfied promise to transfer a distinct good or service that forms part of a single performance obligation, and the terms of that variable consideration relate specifically to the Company’s efforts to transfer the distinct service, or to a specific outcome from transferring the distinct service. The Company’s contracts primarily include monthly fees associated with unspecified quantities of medications, members, claims, medication safety reviews, or user subscriptions that fluctuate throughout the contract. See below for a description of the Company’s revenues. ​ CareVention HealthCare ​ PACE Product Revenue ​ The Company provides medication fulfillment pharmacy services to PACE organizations. While the majority of medications are routinely filled in order to treat chronic conditions, the mix and quantity of medications can vary. Revenue from medication fulfillment services is generally billed monthly or weekly, depending on whether the PACE organization is contracted with a pharmacy benefit manager, and is recognized when medications are delivered and control has passed to the client. At the time of delivery, the Company has performed substantially all of its performance obligations under its client contracts. The Company does not experience a significant level of returns or reshipments. ​ PACE Solutions ​ The Company provides medication safety services and health plan management services to PACE organizations. These services primarily include medication reviews, risk adjustment services, third-party administration services, pharmacy benefit management (“PBM”) solutions, and electronic health records software. Revenue related to these services primarily consists of a fixed monthly fee assessed based on number of members served (“per member per month”), a fee for each claim adjudicated, and subscription fees. These fees are recognized when the Company satisfies its performance obligation to stand ready to provide PACE services, which occurs when the Company’s clients have access to the PACE services. The Company generally bills for PACE services on a monthly basis. ​ For client contracts for which the Company performs both medication fulfillment and PBM services, the Company recognizes revenue using the gross method at the contract price negotiated with its clients and when the Company has concluded it controls the prescription drug before it is transferred to the client plan members. The Company controls prescription drugs dispensed indirectly through its retail pharmacy network because it has separate contractual arrangements with those pharmacies, has discretion in setting the price for the transaction, and assumes primary responsibility for fulfilling the promise to provide prescription drugs to its client plan members while performing the related PBM services. These factors indicate that the Company is the principal and, as such, the Company recognizes the total prescription price contracted with clients in revenue. ​ MedWise HealthCare ​ Medication Safety Services ​ The Company provides medication safety services, which include identification of high-risk individuals, medication regimen reviews including patient and prescriber counseling, and targeted interventions to increase adherence and close gaps in care. Revenue related to these services primarily consists of per member per month fees and fees for each medication review and clinical assessment completed. Revenue is recognized when the Company satisfies its performance obligation to stand ready to provide medication safety services, which occurs when the Company’s clients have access to the medication safety services and when medication reviews and clinical assessments are completed. The Company generally bills for the medication reviews and clinical assessments when they are completed. The Company generally bills for the medication safety services on a monthly basis. ​ Software Subscription and Services ​ The Company provides software as a service (“SaaS”) solutions which allow for the identification of individuals with high medication-related risk and for optimizing medication therapy. Revenues related to these software services primarily consist of monthly subscription fees and are recognized monthly as the Company meets its performance obligation to provide access to the software. Revenue for implementation and set-up services is generally recognized over the contract term as the software services are provided. The Company generally bills for the software services on a monthly basis. ​ Disaggregation of Revenue ​ In the following table, revenue is disaggregated by operating segment. Substantially all of the Company’s revenue is recognized in the U.S. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ ​ ​ 2022 ​ ​ 2021 ​ ​ 2022 ​ ​ 2021 CareVention HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE product revenue ​ $ 55,892 ​ $ 46,858 ​ $ 106,865 ​ $ 88,700 PACE solutions ​ ​ 15,853 ​ ​ 14,347 ​ ​ 31,188 ​ ​ 28,266 ​ ​ $ 71,745 ​ $ 61,205 ​ $ 138,053 ​ $ 116,966 MedWise HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Medication safety services ​ $ 774 ​ $ 3,037 ​ $ 1,493 ​ $ 5,997 Software subscription and services ​ ​ 78 ​ ​ 55 ​ ​ 161 ​ ​ 112 ​ ​ $ 852 ​ $ 3,092 ​ $ 1,654 ​ $ 6,109 Total revenue ​ $ 72,597 ​ $ 64,297 ​ $ 139,707 ​ $ 123,075 ​ Contract Balances ​ Assets and liabilities related to the Company’s contracts are reported on a contract-by-contract basis at the end of each reporting period. Contract balances consist of contract assets and contract liabilities. Contract assets are recorded when the right to consideration for services is conditional on something other than the passage of time. Contract assets relating to unbilled receivables are transferred to accounts receivable when the right to consideration becomes unconditional. Contract assets are classified as current or non-current based on the timing of the Company’s rights to the unconditional payments. Contract assets are generally classified as current and recorded within other current assets on the Company’s consolidated balance sheets. ​ Contract liabilities include advance customer payments and billings in excess of revenue recognized. The Company generally classifies contract liabilities in accrued expenses and other current liabilities and in other long-term liabilities on the Company’s consolidated balance sheets. The Company anticipates that it will satisfy most of its performance obligations associated with its contract liabilities within one year. ​ The following table provides information about the Company’s contract assets and contract liabilities from contracts with clients as of June 30, 2022 and December 31, 2021. ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2022 2021 Contract assets ​ $ 22,043 ​ $ 12,695 Contract liabilities ​ ​ 2,902 ​ ​ 2,191 ​ Significant changes in the contract assets and the contract liabilities balances during the period are as follows: ​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2022 Contract assets: ​ ​ ​ Contract assets, beginning of period ​ $ 12,695 Decreases due to cash received ​ ​ (10,627) Changes to the contract assets at the beginning of the period as a result of changes in estimates ​ ​ 2,915 Changes during the year, net of reclassifications to receivables ​ ​ 17,060 Contract assets, end of period ​ $ 22,043 ​ ​ ​ ​ Contract liabilities: ​ ​ ​ Contract liabilities, beginning of period ​ $ 2,191 Revenue recognized that was included in the contract liabilities balance at the beginning of the period ​ ​ (1,810) Increases due to cash received, excluding amounts recognized as revenue during the year ​ ​ 2,521 Contract liabilities, end of period ​ $ 2,902 ​ During the six months ended June 30, 2021, the Company recognized $1,243 of revenue that was included in the December 31, 2020 contract liability balance of $1,982.

Net Loss per Share

Net Loss per Share	6 Months Ended
	Jun. 30, 2022
Net Loss per Share
Net Loss per Share	5. Net Loss per Share ​ Basic and diluted net loss per share is computed by dividing net loss by the weighted average number of shares of common stock of the Company outstanding during the period. ​ The following table presents the calculation of basic and diluted net loss per share for the Company’s common stock: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ 2022 2021 2022 2021 Numerator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss from continuing operations ​ $ (12,691) ​ $ (14,068) ​ $ (33,083) ​ $ (27,444) Net loss from discontinued operations ​ ​ (36,919) ​ ​ (7,013) ​ ​ (44,720) ​ ​ (13,129) Net loss ​ $ (49,610) ​ $ (21,081) ​ $ (77,803) ​ $ (40,573) Denominator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares of common stock outstanding, basic and diluted ​ ​ 23,959,726 ​ ​ 23,268,131 ​ ​ 23,913,050 ​ ​ 23,140,043 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share from continuing operations, basic and diluted ​ $ (0.53) ​ $ (0.60) ​ $ (1.38) ​ $ (1.19) Net loss per share from discontinued operations, basic and diluted ​ ​ (1.54) ​ ​ (0.31) ​ ​ (1.87) ​ ​ (0.56) Total net loss per share, basic and diluted ​ $ (2.07) ​ $ (0.91) ​ $ (3.25) ​ $ (1.75) ​ The following potential common shares, presented based on amounts outstanding as of June 30, 2022 and 2021, were excluded from the calculation of diluted net loss per share for the periods indicated because including them would have had an anti-dilutive effect. ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2022 2021 Stock options to purchase common stock ​ 1,448,537 ​ 1,741,465 Unvested restricted stock and restricted stock units ​ 2,324,497 ​ 1,658,481 Common stock warrants ​ 4,646,393 ​ 4,646,393 Conversion of convertible senior subordinated notes ​ 4,646,393 ​ 4,646,393 ​ ​ 13,065,820 ​ 12,692,732 ​ ​ For the three and six months ended June 30, 2022 and 2021, shares related to the conversion of the convertible senior subordinated notes were included in the table above using the if-converted method. ​ For the three and six months ended June 30, 2022, shares related to the performance stock units were excluded from the table above, as the performance conditions were unmet as of June 30, 2022 (see Note 13).

Other Current Assets

Other Current Assets	6 Months Ended
	Jun. 30, 2022
Other Current Assets
Other Current Assets	6. Other Current Assets ​ As of June 30, 2022 and December 31, 2021, other current assets consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 December 31, 2021 Contract assets ​ $ 22,043 ​ $ 12,695 Non-trade receivables ​ ​ 778 ​ ​ 3,289 Other ​ ​ 2,200 ​ ​ 2,049 Total other current assets ​ $ 25,021 ​ $ 18,033 ​

Property and Equipment

Property and Equipment	6 Months Ended
	Jun. 30, 2022
Property and Equipment.
Property and Equipment	7. Property and Equipment ​ Accumulated depreciation was $18,131 and $17,427 as of June 30, 2022 and December 31, 2021, respectively. Depreciation expense on property and equipment for the three months ended June 30, 2022 and 2021 was $1,214 and $900 , respectively. Depreciation expense on property and equipment for the six months ended June 30, 2022 and 2021 was ​

Software Development Costs

Software Development Costs	6 Months Ended
	Jun. 30, 2022
Software Development Costs
Software Development Costs	8. Software Development Costs ​ The Company capitalizes certain costs incurred in connection with obtaining or developing its proprietary software platforms, which support its product and service contracts. These costs include third-party contractors and payroll for employees directly involved with the software development, including external direct costs of material and services, and interest expense related to the borrowings attributable to software development. As of June 30, 2022 31, ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 December 31, 2021 Software development costs $ 46,750 ​ $ 49,481 Less: accumulated amortization ​ (15,475) ​ ​ (20,227) Software development costs, net $ 31,275 ​ $ 29,254 ​ ​ ​ ​ ​ ​ Capitalized software development costs included above not yet subject to amortization $ 8,379 ​ $ 5,328 ​ Amortization expense for the three months ended June 30, 2022 and 2021 was $2,581 and $2,165, respectively. Amortization expense for the six months ended June 30, 2022 and 2021 was $5,781 and $4,103, respectively. ​ During the first quarter of 2022, the Company became aware of changes in circumstances impacting the future functionality of certain capitalized software development costs in the MedWise HealthCare segment and evaluated the recoverability of the related long-lived assets by comparing their carrying amount to the future net undiscounted cash flows expected to be generated by the assets to determine if the carrying value was not recoverable. The recoverability test indicated that certain capitalized software development costs were impaired and, as a result, the Company used an income approach to measure the fair value of the assets and recognized non-cash impairment charges of $4,062 for the six months ended June 30, 2022. There were no identified circumstances that would impact the future functionality of capitalized software development costs during the three months ended June 30, 2022.

Goodwill and Intangible Assets

Goodwill and Intangible Assets	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets
Goodwill and Intangible Assets	9. Goodwill and Intangible Assets ​ The Company’s goodwill as of June 30, 2022 and December 31, 2021 was $115,323, which relates to the Company’s CareVention HealthCare segment. ​ During the first and second quarters of 2022, the Company experienced a sustained decline in the market price of its common stock and determined that an indicator of impairment was present. The Company performed a quantitative goodwill impairment assessment as of June 30, 2022, estimating the fair value of the Company’s reporting unit using a market approach. Based on the analysis performed, the Company determined that the estimated fair value of the Company’s reporting unit exceeded its carrying value, and, as a result, goodwill was not impaired as of June 30, 2022. ​ Intangible assets consisted of the following as of June 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 2.9 ​ $ 1,340 ​ $ (939) ​ $ 401 Client relationships ​ 11.7 ​ ​ 51,264 ​ ​ (13,306) ​ ​ 37,958 Non-competition agreements ​ 5.0 ​ ​ 1,640 ​ ​ (1,139) ​ ​ 501 Developed technology ​ 6.2 ​ ​ 14,720 ​ ​ (11,640) ​ ​ 3,080 Domain name ​ 10.0 ​ ​ 59 ​ ​ (29) ​ ​ 30 Total intangible assets ​ ​ ​ $ 69,023 ​ $ (27,053) ​ $ 41,970 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 2.9 ​ $ 1,340 ​ $ (853) ​ $ 487 Client relationships ​ 11.7 ​ ​ 51,264 ​ ​ (11,042) ​ ​ 40,222 Non-competition agreements ​ 5.0 ​ ​ 1,640 ​ ​ (975) ​ ​ 665 Developed technology ​ 6.2 ​ ​ 14,720 ​ ​ (10,768) ​ ​ 3,952 Domain name ​ 10.0 ​ ​ 59 ​ ​ (27) ​ ​ 32 Total intangible assets ​ ​ ​ $ 69,023 ​ $ (23,665) ​ $ 45,358 ​ Amortization expense for intangible assets for the three months ended June 30, 2022 and 2021 was $1,695 and $1,915, respectively. Amortization expense for intangible assets for the six months ended June 30, 2022 and 2021 was $3,389 and $3,831, respectively. ​ The estimated amortization expense for the remainder of 2022 and each of the next five years and thereafter is as follows: ​ ​ ​ ​ ​ Years Ending December 31, ​ ​ 2022 (July 1 – December 31) ​ $ 3,363 2023 ​ ​ 6,162 2024 ​ ​ 4,684 2025 ​ ​ 4,466 2026 ​ ​ 4,338 2027 ​ ​ 4,271 Thereafter ​ ​ 14,686 Total estimated amortization expense ​ $ 41,970 ​

Accrued Expenses and Other Liab

Accrued Expenses and Other Liabilities	6 Months Ended
	Jun. 30, 2022
Accrued Expenses and Other Liabilities
Accrued Expenses and Other Liabilities	10. Accrued Expenses and Other Liabilities ​ As of June 30, 2022 and December 31, 2021, accrued expenses and other liabilities consisted of the following: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 December 31, 2021 Employee related expenses ​ $ 5,442 ​ $ 8,595 Contract liability ​ ​ 2,751 ​ ​ 2,015 Customer deposits ​ ​ 904 ​ ​ 904 Client funds obligations* ​ ​ 7,062 ​ ​ 6,038 Contract labor ​ ​ 2,331 ​ ​ 838 Interest ​ ​ 2,340 ​ ​ 2,281 Vendor financing arrangements ​ ​ 96 ​ ​ — Professional fees ​ ​ 1,438 ​ ​ 1,327 Consideration payable to customer ​ ​ 24,587 ​ ​ 15,971 Income and non-income taxes payable ​ ​ 45 ​ ​ 15 Other expenses ​ ​ 3,183 ​ ​ 3,013 Total accrued expenses and other liabilities ​ $ 50,179 ​ $ 40,997 ​ *This amount represents client funds held by the Company, with an offsetting amount included in restricted cash.

Lines of Credit and Long-Term D

Lines of Credit and Long-Term Debt	6 Months Ended
	Jun. 30, 2022
Lines of Credit and Long-Term Debt
Lines of Credit and Long-Term Debt	11. Lines of Credit and Long-Term Debt ​ (a) Lines of Credit ​ On December 18, 2020, the Company and its subsidiaries entered into a Loan and Security Agreement (the “2020 Credit Facility”), with Western Alliance Bank (“WAB”). The 2020 Credit Facility provided for a $120,000 secured revolving credit facility, with a $1,000 sublimit for cash management services and letters of credit and foreign exchange transactions. ​ Amounts under the 2020 Credit Facility could be borrowed, repaid, and re-borrowed from time to time until the maturity date on May 16, 2025, and were permitted to be used for, among other things, working capital and other general corporate purposes. Loans under the 2020 Credit Facility bore interest at a rate equal to the LIBOR rate plus 3.25%. In the event LIBOR for any applicable interest period was less than zero percent, then the LIBOR rate would have been determined as zero percent for such interest period. If LIBOR ceased to exist or was no longer available, then the interest rate would have been replaced with an alternate base rate and spread. The obligations under the 2020 Credit Facility were secured by all of the assets of the borrowers, subject to certain exceptions and exclusions as set forth in the 2020 Credit Facility. ​ The 2020 Credit Facility contained certain affirmative and negative covenants that were binding on the Company, including, but not limited to, restrictions (subject to specified exceptions and qualifications) on the Company’s ability to incur indebtedness, create liens, merge or consolidate, make dispositions, pay dividends or make distributions, make investments, pay any subordinated indebtedness, enter into certain transactions with affiliates, or make capital expenditures. In addition, the 2020 Credit Facility imposed certain financial covenants, including that the Company (i) maintain unrestricted cash balances with WAB, plus amounts available for draw under the 2020 Credit Facility of at least $10,000 at all times, and (ii) maintain a leverage ratio of less than 3.00:1.00, on a trailing twelve-month twelve months ​ The 2020 Credit Facility was subject to a commitment fee of 0.50% of the total commitment amount payable on the closing date, and 0.25% of the total commitment amount payable on each anniversary thereafter. Additionally, the 2020 Credit Facility was subject to an unused line fee. ​ As of June 30, 2022, the Company had $57,200 outstanding under the 2020 Credit Facility, plus an outstanding letter of credit of $100 issued in connection with the Company’s lease agreement for its office space in Moorestown, New Jersey. The letter of credit renewed annually until its expiration in September 2027, and reduced amounts available under the 2020 Credit Facility. As discussed in Note 18, on August 1, 2022, the Company entered into payoff letter with WAB pursuant to which the Company voluntarily elected to pay all amounts outstanding under the 2020 Credit Facility and terminated the 2020 Credit Facility and all related loan documents. ​ As of June 30, 2022, the interest rate on the 2020 Credit Facility was 4.37% and the effective rate for the unused line fee was 0.35%. Interest expense on the 2020 Credit Facility was $637 and $1,097 for the three and six months ended June 30, 2022, respectively. As of June 30, 2021, the interest rate on the 2020 Credit Facility was 3.34% and the effective rate for the unused line fee was 0.45%. Interest expense on the 2020 Credit Facility was $267 and $528 for the three and six months ended June 30, 2021, respectively. ​ In connection with the 2020 Credit Facility, the Company recorded deferred financing costs of $1,534. The Company is amortizing the deferred financing costs associated with the 2020 Credit Facility to interest expense using the effective-interest method over the term of the agreement. The Company amortized $138 and $275 to interest expense for the three and six months ended June 30, 2022, respectively, for deferred financing costs. The Company amortized $135 and $268 to interest expense during the three and six months ended June 30, 2021, respectively, for deferred financing costs. Deferred financing costs of $699 and $624, net of accumulated amortization, are included in other assets on the accompanying consolidated balance sheets as of June 30, 2022 and December 31, 2021, respectively. The remaining balance of deferred financing costs will be amortized to interest expense during the third quarter of 2022 in connection with the termination of the 2020 Credit Facility as described in Note 18. ​ (b) Convertible Senior Subordinated Notes ​ On February 12, 2019, the Company issued and sold an aggregate principal amount of $325,000 of 1.75% convertible senior subordinated notes (the “2026 Notes”) in a private placement pursuant to Rule 144A under the Securities Act of 1933, as amended. The 2026 Notes bear interest at a rate of 1.75% per year, payable semiannually in arrears on February 15 and August 15 of each year, beginning on August 15, 2019. The 2026 Notes will mature on February 15, 2026, unless earlier converted or repurchased. The initial conversion rate for the notes is 14.2966 shares of the Company’s common stock per $1 principal amount of the 2026 Notes. This conversion rate is equal to an initial conversion price of approximately $69.95 per share of the Company’s common stock. ​ Holders may convert all or any portion of their at any time prior to the close of business on the business day immediately preceding August 15, 2025 only under the following circumstances: (1) during any calendar quarter commencing after March 31, 2019 (and only during such calendar quarter), if the last reported sale price of the Company’s common stock for at least 20 trading days (whether or not consecutive) during a period of 30 consecutive trading days ending on the last trading day of the immediately preceding calendar quarter is greater than or equal to 130% of the conversion price on each applicable trading day; (2) during the five business day period after any five consecutive trading day period (the measurement period) in which the trading price (as defined in the indenture governing the 2026 Notes) per $1 principal amount of 2026 Notes for each trading day of the measurement period was less than 98% of the product of the last reported sale price of the Company’s common stock and the conversion rate on each such trading day; or (3) upon the occurrence of specified corporate events, including certain distributions, the occurrence of a fundamental change or make-whole fundamental change (as defined in the indenture governing the 2026 Notes) or a transaction resulting in the Company’s common stock converting into other securities or property or assets. On or after August 15, 2025 until the close of business on the first scheduled trading day immediately preceding the maturity date, a holder may convert all or any portion of its 2026 Notes regardless of the foregoing circumstances. Upon conversion, the Company will pay or deliver shares of our common stock, cash or a combination thereof at the Company’s option. As of June 30, 2022, none of the conditions allowing holders of the 2026 Notes to convert had been met. Debt issuance costs related to the 2026 Notes of $9,372 are being amortized to interest expense using the effective interest method over the contractual term, resulting in ​ During the three months ended June 30, 2022, the Company recognized $1,755 of interest expense related to the 2026 Notes, of which $1,422 was paid or accrued and $333 was non-cash accretion of the debt discounts recorded. During the six months ended June 30, 2022, the Company recognized $3,508 of interest expense related to the 2026 Notes, of which $2,844 was paid or accrued and $664 was non-cash accretion of the debt discounts recorded. ​ During the three months ended June 30, 2021, the Company recognized $1,747 of interest expense related to the 2026 Notes, of which $1,421 was paid or accrued, and $326 was non-cash accretion of the debt discounts recorded. During the six months ended June 30, 2021, the Company recognized $3,493 of interest expense related to the 2026 Notes, of which $2,843 was paid or accrued, and $650 was non-cash accretion of the debt discounts recorded. ​ As of June 30, 2022, total accrued interest payable related to the 2026 Notes was $2,133 , which is included in accrued expenses and other liabilities on the consolidated balance sheets. The 2026 Notes have a carrying value of $319,963 as of June 30, 2022. ​ (c) Convertible Note Hedge and Warrant Transactions ​ In connection with the offering of the 2026 Notes, the Company entered into convertible note hedge transactions with affiliates of certain of the initial purchasers (the “option counterparties”) of the 2026 Notes pursuant to the terms of call option confirmations. The Company has the option to purchase a total of 4,646,393 shares of its common stock at a price of approximately As these instruments are considered indexed to the Company's own stock and are considered equity classified, the convertible note hedges and warrants are recorded in stockholders’ equity, are not accounted for as derivatives and are not remeasured each reporting period. The net costs incurred in connection with the convertible note hedge and warrant transactions were recorded as a reduction to additional paid-in capital on the Company’s consolidated balance sheets. ​ The convertible note hedge transactions are expected generally to reduce the potential dilution to the Company’s common stock upon conversion of the 2026 Notes and/or offset any potential cash payments the Company is required to make in excess of the principal amount of converted 2026 Notes, as the case may be. The warrant transactions could separately have a dilutive effect on the Company’s common stock to the extent that the market price per share of the Company’s common stock exceeds the strike price of the warrants. ​ As of June 30, 2022, no warrants have been exercised and all warrants to purchase shares of the Company’s common stock were outstanding. ​ (d) Long-Term Debt ​ The following table represents the total long-term debt obligations of the Company at June 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 December 31, 2021 Convertible senior subordinated notes ​ $ 235,272 ​ $ 325,000 Convertible senior subordinated notes - related party ​ ​ 89,728 ​ ​ — Unamortized discount, including debt issuance costs, on convertible senior subordinated notes ​ ​ (5,037) ​ ​ (5,701) Total long-term debt, net ​ $ 319,963 ​ $ 319,299 ​

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2022
Income Taxes
Income Taxes	12. Income Taxes ​ For the three months ended June 30, 2022 and 2021, the Company recorded income tax expense of $159 and $81, respectively, which resulted in effective tax rates of (1.3%) and (0.6)%, respectively. ​ For the six months ended June 30, 2022 and 2021, the Company recorded income tax expense of $375 and $202, respectively, which resulted in effective tax rates of (1.1%) and (0.7)%, respectively. ​ The effective tax rates differ from the U.S. statutory tax rate primarily due to the full valuation allowance recorded that is currently limiting the realizability of the Company’s net deferred tax assets as of the end of the periods presented. Accordingly, the tax benefit was limited due to unbenefited losses in the three and six months ended June 30, 2022 and 2021, respectively. ​ On February 12, 2021, the Company received a private letter ruling from the Internal Revenue Service, which determined, based on information submitted and representations made by the Company, that the Company met the requirements to deduct the interest expense resulting from the amortization of the debt discount associated with the 2026 Notes. As a result, the Company recorded a deferred tax asset of $26,313 and a corresponding $26,313 increase to its valuation allowance.

Stock-Based Compensation

Stock-Based Compensation	6 Months Ended
	Jun. 30, 2022
Stock-Based Compensation
Stock-Based Compensation	13. Stock-Based Compensation ​ In September 2016, the Company adopted the 2016 Equity Compensation Plan ( ​ ​ Restricted Common Stock and Restricted Stock Units ​ The Company issues restricted stock awards and restricted stock units pursuant to the 2016 Plan to employees and non-employee directors. Restricted stock awards and restricted stock units generally vest over a one ​ The following table summarizes the aggregate restricted stock award activity, inclusive of performance based restricted stock awards, and restricted stock unit activity under the 2016 Plan for the six months ended June 30, 2022.: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ Number ​ grant-date ​ of shares fair value Outstanding at December 31, 2021 ​ 2,196,566 ​ $ 40.19 Granted ​ 768,351 ​ ​ 5.32 Vested ​ (456,774) ​ ​ 44.01 Forfeited ​ (169,424) ​ ​ 36.67 Outstanding at June 30, 2022 ​ 2,338,719 ​ $ 28.24 ​ The table above includes 14,222 restricted stock units which have vested but as of June 30, 2022, have not been issued. ​ For the three months ended June 30, 2022 and 2021, an aggregate of $5,681 and $10,124 of expense, respectively, was recognized related to restricted stock awards and restricted stock units, excluding performance-based restricted stock awards described below. ​ For the six months ended June 30, 2022 and 2021, an aggregate of $13,068 and $16,399 of expense, respectively, was recognized related to restricted stock awards and restricted stock units, excluding performance-based restricted stock awards as described below. As of June 30, 2022, there was unrecognized compensation expense of $44,394 related to unvested restricted stock awards and unvested restricted stock units, excluding performance-based restricted stock awards described below, under the 2016 Plan, which is expected to be recognized over a weighted average period of 2.4 years. ​ Performance-Based Equity Awards ​ On May 4, 2020, pursuant to the 2016 Plan, the Board approved grants totaling 10,686 shares of restricted stock to an employee. The grants were recorded using a grant-date fair value of $56.14 per share which was based on the Company’s closing stock price on the grant date. The grants were subject to certain performance conditions for the two-year period ended March 2, 2022, which were not achieved. As a result, the grants expired, and no expense was recognized during the six months ended June 30, 2022. ​ On October 29, 2020, pursuant to the 2016 Plan, the Board approved grants totaling 26,400 shares of restricted stock to certain employees, of which 1,400 expired on April 30, 2021 and 12,500 expired on December 31, 2021. The remaining 12,500 shares fully vested subject to the achievement of certain milestones on December 31, 2021. The awards had a grant-date fair value of $35.95 per share based on the Company’s closing stock price on the grant date. Stock-based compensation costs associated with these grants were recognized over the service period based upon the Company’s assessment of the probability that the performance conditions would be achieved. The Company recognized $148 and $362 of stock-based compensation expense related to these grants for the three and six months ended June 30, 2021, respectively. ​ On April 27, 2021, pursuant to the 2016 Plan, the Board approved awards of performance stock units to certain employees. Each award reflects a target number of shares (“Target Shares”) that may be issued to the award recipient. As of June 30, 2022, the number of Target Shares was 86,175 shares. The awards are earned upon the Company’s achievement of certain revenue performance targets during the three-year performance period ending December 31, 2023. Depending on the results achieved during the performance period, the actual number of shares that a grant recipient may receive at the end of the performance period may range from 0% to 200% of the Target Shares granted. The performance stock unit awards have a grant-date fair value of $44.13 per share based on the Company’s closing stock price on the grant date. Stock-based compensation costs associated with these grants are recognized over the performance period based upon the Company’s assessment of the probability that the performance targets will be achieved. The Company did not recognize any stock-based compensation expense related to the performance stock units, resulting in no stock-based compensation expense for the three and six months ended June 30, 2022, as the achievement of the underlying performance targets was considered unlikely. During the six months ended June 30, 2022, 6,550 performance stock units expired. As of June 30, 2022, the maximum number of achievable performance stock units was 172,350 and the maximum unrecognized compensation expense was $7,606 . ​ Other Stock Awards ​ During the first quarter of 2021, the Board approved the grant of stock awards to certain non-employee directors and to a consultant pursuant to the 2016 Plan. The awards provided for the issuance of 1,416 shares of the Company’s common stock, which immediately vested on the grant date. These grants had a weighted average grant-date fair value of $40.85 per share. For the six months ended June 30, 2021, the Company recorded $58 of expense related to these stock awards. ​ During the first quarter of 2022, the Board approved grants of stock awards to certain non-employee directors and employees pursuant to the 2016 Plan. The awards provided for the issuance of 16,471 shares of the Company’s common stock, which immediately vested on the grant date. These grants had a weighted average grant-date fair value of $5.57 per share. For the six months ended June 30, 2022, the Company recorded $92 of expense related to these stock awards. ​ During the second quarter of 2022, the Board approved grants of stock awards to certain non-employee directors pursuant to the 2016 Plan. The awards provided for the issuance of 12,262 shares of the Company’s common stock, which immediately vested on the grant date. These grants had a weighted average grant-date fair value of $3.64 per share. For the three months ended June 30, 2022, the Company recorded $45 of expense related to these stock awards. ​ Stock Options ​ The Company recorded $966 and $1,861 of stock-based compensation expense related to employee and non-employee director stock options for the three months ended June 30, 2022 and 2021, respectively. The Company recorded $2,096 and $3,916 of stock-based compensation expense related to employee and non-employee stock options for the six months ended June 30, 2022 and 2021, respectively. The Company records forfeitures as they occur. ​ No grants for employee and non-employee stock options were made during the six months ended June 30, 2022. The table below sets forth the weighted average assumptions for employee grants during the six months ended June 30, 2021: ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ Valuation assumptions: June 30, 2021 ​ Expected volatility ​ 58.57 % Expected term (years) ​ 5.48 ​ Risk-free interest rate ​ 0.50 % Dividend yield ​ — ​ ​ The weighted average grant date fair value of employee options granted during the six months ended June 30, 2021 was $28.26 per share. ​ The following table summarizes stock option activity under the 2016 Plan for the six months ended June 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Weighted ​ average ​ ​ ​ ​ ​ ​ ​ average ​ remaining ​ Aggregate ​ ​ Number ​ exercise ​ contractual ​ intrinsic ​ of shares price term value Outstanding at December 31, 2021 ​ 1,604,226 ​ $ 29.90 ​ ​ ​ ​ Exercised ​ (12,573) ​ ​ 5.01 ​ ​ ​ ​ ​ Forfeited ​ (143,116) ​ ​ 46.27 ​ ​ ​ ​ ​ Outstanding at June 30, 2022 ​ 1,448,537 ​ $ 28.49 ​ 4.9 ​ $ - Options vested and expected to vest at June 30, 2022 ​ 1,448,537 ​ $ 28.49 ​ 4.9 ​ $ - Exercisable at June 30, 2022 ​ 1,379,541 ​ $ 27.16 ​ 4.8 ​ $ - ​ The aggregate intrinsic value of stock options is calculated as the difference between the exercise price of the stock options and the Company’s closing stock price or estimated fair value on the last trading day of the fiscal quarter for those stock options that had exercise prices lower than the fair value of the Company's common stock. This amount changes based on the fair market value of the Company’s stock. The total intrinsic value of options exercised during the six months ended June 30, 2022 and 2021 was $2 and $10,601, respectively. ​ As of June 30, 2022, there was $2,057 of total unrecognized compensation cost related to nonvested stock options granted under the 2016 Plan, which is expected to be recognized over a weighted average period of 0.6 years. ​ Cash received from option exercises for the six months ended June 30, 2022 and 2021 was $60 and $3,082, respectively. ​ The Company recorded total stock-based compensation expense for the three and six months ended June 30, 2022 and 2021 in the following expense categories of its consolidated statements of operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ 2022 2021 2022 2021 Cost of revenue - product ​ $ 223 ​ $ 337 ​ $ 447 ​ $ 596 Cost of revenue - service ​ ​ 570 ​ ​ 898 ​ ​ 1,471 ​ ​ 1,748 Research and development ​ ​ 761 ​ ​ 2,069 ​ ​ 2,280 ​ ​ 3,272 Sales and marketing ​ ​ 50 ​ ​ 345 ​ ​ 308 ​ ​ 1,042 General and administrative ​ ​ 3,488 ​ ​ 6,178 ​ ​ 8,289 ​ ​ 10,541 Discontinued operations ​ ​ 1,600 ​ ​ 2,522 ​ ​ 2,506 ​ ​ 3,752 Total stock-based compensation expense ​ $ 6,692 ​ $ 12,349 ​ $ 15,301 ​ $ 20,951 ​ ​ ​ Employee Stock Purchase Plan In February 2021, the Board, subject to stockholder approval, adopted the Tabula Rasa HealthCare, Inc. Employee Stock Purchase Plan (the “ESPP”), which allows eligible employees to purchase common shares of Company stock through payroll deductions at a 15% discount off the lower of (i) the fair market value per share of common stock on the start date of the applicable offering period or (ii) the fair market value per share of common stock on the purchase date. The ESPP was approved by the Company’s stockholders at the 2021 annual meeting of stockholders in June 2021. The number of shares of common stock reserved for issuance under the ESPP will initially be 480,097 shares, subject to adjustment as provided in the ESPP, all of which remained available as of June 30, 2022.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2022
Fair Value Measurements
Fair Value Measurements	14. Fair Value Measurements ​ The Company’s financial instruments consist of accounts receivable, client claims receivables, contract assets, accounts payable, client claims payable, contract liabilities, accrued expenses, vendor financing arrangements, line of credit, and long-term debt, which includes the Company’s convertible senior subordinated notes. The carrying values of accounts receivable, client claims receivables, contract assets, accounts payable, client claims payable, contract liabilities, and accrued expenses are representative of their fair values due to the relatively short-term nature of those instruments. Vendor financing arrangements are recorded at net carrying value, which approximates fair value. The outstanding principal balance of the line of credit is representative of its fair value due to it being variable-rate debt. See below for additional information on the Company’s convertible senior subordinated notes. ​ The following table presents the financial instruments that are not carried at fair value but require fair value disclosure as of June 30, 2022: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Face Value Carrying Value Fair Value 1.75% Convertible Senior Subordinated Notes due 2026 ​ $ 325,000 ​ $ 319,963 ​ $ 219,193 ​ The fair value of the 2026 Notes at each balance sheet date is determined based on recent quoted market prices for these notes which is a Level 2 measurement. As discussed in Note 11, the 2026 Notes are carried at their aggregate face value of $325,000 , less any unamortized debt issuance costs.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2022
Commitments and Contingencies
Commitments and Contingencies	15. Commitments and Contingencies ​ (a) Employment Agreements ​ The Company has change-in-control and severance agreements with each of the Company’s named executive officers that provide for, among other things, salary, performance bonuses or other incentive compensation, payments in the event of termination of the executives upon the occurrence of a change in control, and restrictive covenants pursuant to which the employees have agreed to refrain from competing with the Company or soliciting the Company’s employees or clients for a period following the employee’s termination of employment. ​ (b) Legal Proceedings ​ The Company is not currently involved in any significant claims or legal actions that, in the opinion of management, are expected to have a material adverse impact on the Company. ​ (c) Vendor Purchase Agreements ​ On March 29, 2019, the Company entered into an Affiliated Pharmacy Agreement and Pharmaceutical Program Supply Agreement (the “Prior Thrifty Drug Agreements”) with Thrifty Drug Stores, Inc. (“Thrifty Drug”). On July 1, 2020, the Company entered into a new Affiliated Pharmacy Agreement and Pharmaceutical Program Supply Agreement with Thrifty Drug (the “Thrifty Drug Agreements”) to replace the Prior Thrifty Drug Agreements, which, among other things, extended the Company’s agreement with Thrifty Drug through September 30, 2023. Pursuant to the terms of the Thrifty Drug Agreements, the Company has agreed to purchase not less than 98% of the Company’s total prescription product requirements from Thrifty Drug. The Company commenced purchasing prescription products under the Prior Thrifty Drug Agreements in May 2019 and has continued to do so under the Thrifty Drug Agreements beginning in July 2020. Both the Prior Thrifty Drug Agreements and the Thrifty Drug Agreements authorize Thrifty Drug to hold a security interest in all of the products purchased by the Company under the respective agreements. ​ As of June 30, 2022 and December 31, 2021 the Company had $1,723 and $1,854, respectively, due to Thrifty Drug as a result of prescription drug purchases. ​ In December 2019, the Company entered into an updated agreement with its data aggregation partner related to the Company’s pharmacy cost management services. The agreement is effective January 1, 2020 with a three-year term expiring December 31, 2022 and commits the Company to a monthly minimum purchase obligation of $30. ​ In June 2021, the Company entered into an updated agreement with its provider of hosting services. The agreement is effective June 3, 2021 and expires on April 28, 2024 and commits the Company to a minimum purchase obligation of $1,272 over the contract term. As of June 30, 2022, the Company had a remaining commitment of $802. ​ In August 2021, the Company entered into an agreement with a third party to provide information technology services. The agreement is effective November 1, 2021 and expires on October 31, 2026 and commits the Company to a minimum purchase obligation of $8,960 through October 31, 2024. As of June 30, 2022, the Company had a remaining commitment of $6,969. ​ In October 2021, the Company entered into an agreement with a provider for enterprise support services. The agreement is effective October 1, 2021 and expires on September 30, 2024. The three-year contract commits the Company to an obligation of $7,050 over the duration of the contract term. As of June 30, 2022, the Company had a remaining commitment of $5,159. ​ In November 2021, the Company entered into an agreement with a new provider for additional hosting services. The agreement is effective November 25, 2021 and expires on November 25, 2022 and commits the Company to a minimum purchase obligation of $1,598 over the contract term. As of June 30, 2022, the Company had a remaining commitment of $729. ​ ​

Segment Reporting

Segment Reporting	6 Months Ended
	Jun. 30, 2022
Segment Reporting
Segment Reporting	16. Segment Reporting ​ The Company operates its business through two segments. As discussed in Note 3 above, the divestiture of the PrescribeWellness business and the planned SinfoníaRx businesses, which collectively comprise the majority of the Company’s MedWise HealthCare segment, ​ The Company's chief operating decision maker (“CODM”), the Chief Executive Officer, allocates resources and assesses performance based upon financial information at the reportable segment level. Substantially all revenues are generated and substantially all tangible assets are held in the U.S. ​ CareVention HealthCare primarily provides services to PACE organizations that include medication fulfillment pharmacy services and PACE solutions, such as medication safety services, PBM solutions, and health plan management services . ​ MedWise HealthCare primarily generates revenues from medication safety services and software subscription solutions, ​ Shared services primarily consist of corporate sales and marketing expenses and general and administrative expenses associated with the management and administration of the Company’s business objectives. ​ The CODM uses revenue in accordance with GAAP and Adjusted EBITDA as the relevant segment performance measures to evaluate the performance of the segments and allocate resources. ​ Adjusted EBITDA is a segment performance financial measure that offers a useful view of the overall operation of the Company’s businesses and may be different from similarly titled segment performance financial measures used by other companies. ​ Adjusted EBITDA consists of net loss plus certain other expenses, which include interest expense, income tax expense, depreciation and amortization, impairment charges, settlement costs, business optimization expenses, severance costs, executive transition costs, divestiture-related expense, acquisition-related expense, and stock-based compensation expense. The Company considers settlement costs to include amounts payable by the Company or reductions to amounts owed to the Company as a result of a contractual settlement. The Company considers business optimization expenses to include contract termination payments, severance, retention payments, and other employee and non-recurring vendor costs incurred related to its business optimization initiatives during 2022. The Company considers severance costs to include severance payments related to the realignment of its resources. The Company considers executive transition costs to include nonrecurring costs related to hiring and onboarding of new named executive officers. The Company considers divestiture-related expense to include nonrecurring direct transaction costs. The Company considers acquisition-related expense to include nonrecurring direct transaction and integration costs. ​ Management considers revenue and Adjusted EBITDA to be the appropriate metric to evaluate and compare the ongoing operating performance of the Company’s segments on a consistent basis across reporting periods as it eliminates the effect of items which are not indicative of each segment’s core operating performance. ​ The following tables present the Company’s segment information: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ Shared Services and Other ​ Consolidated Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 55,892 ​ $ — ​ $ 55,892 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 15,853 ​ ​ — ​ ​ 15,853 Medication safety services ​ ​ — ​ ​ 774 ​ ​ 774 Software subscription and services ​ ​ — ​ ​ 78 ​ ​ 78 Total service revenue ​ ​ 15,853 ​ ​ 852 ​ ​ 16,705 Total revenue ​ $ 71,745 ​ $ 852 ​ $ 72,597 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 46,858 ​ $ — ​ $ 46,858 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 14,347 ​ ​ — ​ ​ 14,347 Medication safety services ​ ​ — ​ ​ 3,037 ​ ​ 3,037 Software subscription and services ​ ​ — ​ ​ 55 ​ ​ 55 Total service revenue ​ ​ 14,347 ​ ​ 3,092 ​ ​ 17,439 Total revenue ​ $ 61,205 ​ $ 3,092 ​ $ 64,297 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 106,865 ​ $ — ​ $ 106,865 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 31,188 ​ ​ — ​ ​ 31,188 Medication safety services ​ ​ — ​ ​ 1,493 ​ ​ 1,493 Software subscription and services ​ ​ — ​ ​ 161 ​ ​ 161 Total service revenue ​ ​ 31,188 ​ ​ 1,654 ​ ​ 32,842 Total revenue ​ $ 138,053 ​ $ 1,654 ​ $ 139,707 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 88,700 ​ $ — ​ $ 88,700 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 28,266 ​ ​ — ​ ​ 28,266 Medication safety services ​ ​ — ​ ​ 5,997 ​ ​ 5,997 Software subscription and services ​ ​ — ​ ​ 112 ​ ​ 112 Total service revenue ​ ​ 28,266 ​ ​ 6,109 ​ ​ 34,375 Total revenue ​ $ 116,966 ​ $ 6,109 ​ $ 123,075 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ Shared Services and Other ​ Consolidated Adjusted EBITDA (loss) from Continuing Operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 13,396 ​ $ (11,339) ​ $ 2,057 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 14,059 ​ $ (10,796) ​ $ 3,263 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 25,480 ​ $ (22,341) ​ $ 3,139 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 26,969 ​ $ (22,123) ​ $ 4,846 ​ The following table presents the Company’s reconciliation of the segments’ total Adjusted EBITDA to net loss as presented in the consolidated statements of operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2022 2021 2022 2021 Reconciliation of Net Loss to Adjusted EBITDA from Continuing Operations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (49,610) ​ $ (21,081) ​ $ (77,803) ​ $ (40,573) Add: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense, net ​ ​ 2,444 ​ ​ 2,182 ​ ​ 4,713 ​ ​ 4,729 Income tax expense ​ ​ 159 ​ ​ 81 ​ ​ 375 ​ ​ 202 Depreciation and amortization ​ ​ 5,489 ​ ​ 4,980 ​ ​ 11,231 ​ ​ 9,781 Impairment charges ​ ​ — ​ ​ — ​ ​ 4,062 ​ ​ — Business optimization expenses ​ ​ — ​ ​ — ​ ​ 787 ​ ​ — Severance costs ​ ​ — ​ ​ 162 ​ ​ 575 ​ ​ 162 Executive transition ​ ​ 150 ​ ​ — ​ ​ 150 ​ ​ — Divestiture-related expense ​ ​ 1,414 ​ ​ — ​ ​ 1,534 ​ ​ — Acquisition-related expense ​ ​ — ​ ​ 99 ​ ​ — ​ ​ 217 Stock-based compensation expense ​ ​ 5,092 ​ ​ 9,827 ​ ​ 12,795 ​ ​ 17,199 Loss from discontinued operations ​ ​ 36,919 ​ ​ 7,013 ​ ​ 44,720 ​ ​ 13,129 Adjusted EBITDA from continuing operations ​ $ 2,057 ​ $ 3,263 ​ $ 3,139 ​ $ 4,846 Adjusted EBITDA from discontinued operations ​ ​ 1,117 ​ ​ 2,700 ​ ​ 2,557 ​ ​ 4,716 Total Adjusted EBITDA ​ $ 3,174 ​ $ 5,963 ​ $ 5,696 ​ $ 9,562 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2022 2021 2022 2021 Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss from discontinued operations, net of tax ​ $ (36,919) ​ $ (7,013) ​ $ (44,720) ​ $ (13,129) Add: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income tax (benefit) expense ​ ​ (686) ​ ​ 52 ​ ​ (568) ​ ​ 130 Depreciation and amortization ​ ​ — ​ ​ 6,639 ​ ​ 7,331 ​ ​ 13,463 Impairment charges ​ ​ 35,608 ​ ​ — ​ ​ 36,448 ​ ​ — Settlement ​ ​ 1,448 ​ ​ 500 ​ ​ 1,448 ​ ​ 500 Divestiture-related expense ​ ​ 66 ​ ​ — ​ ​ 112 ​ ​ — Stock-based compensation expense ​ ​ 1,600 ​ ​ 2,522 ​ ​ 2,506 ​ ​ 3,752 Adjusted EBITDA from discontinued operations ​ $ 1,117 ​ $ 2,700 ​ $ 2,557 ​ $ 4,716 ​ Asset information by segment is not a key measure of performance used by the CODM. Accordingly, the Company has not disclosed asset information by segment.

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2022
Related Party Transactions
Related Party Transactions	17. Related Party Transactions ​ The Company’s CareVention HealthCare segment provides medication fulfillment pharmacy services and certain PACE solutions services to a client whose Chief Executive Officer is a member of the Board. For the three months ended June 30, 2022 and 2021, $1,888 and $1,696 , respectively, of revenue related to this client was included in the Company’s consolidated statements of operations. For the six months ended June 30, 2022 and 2021, $3,647 and $3,155 , respectively, of revenue related to this client was included in the Company’s consolidated statements of operations, and $147 and $67 was included in accounts receivable, net, as of June 30, 2022 and December 31, 2021, respectively, on the Company’s consolidated balance sheets. The Company believes that these transactions are on terms comparable to those that the Company could reasonably expect in an arm’s length transaction with an unrelated third party. ​ As of June 30, 2022, a holder of the Company’s convertible senior subordinated notes became a significant stockholder. The stockholder held approximately $88,337 of the Company’s convertible senior subordinated notes, net of discount, which is presented on the Company’s consolidated balance sheet as of June 30, 2022. See Note 11 for more information on the Company’s convertible senior subordinated notes. ​

Subsequent Events

Subsequent Events	6 Months Ended
	Jun. 30, 2022
Subsequent Event
Subsequent Event	18. Subsequent Events ​ a) Closing of Sale of PrescribeWellness Business ​ On August 1, 2022 (the “Closing Date”), the Company completed the sale of the and the acquisition of the KD Assets. At the closing, pursuant to the terms of the PW Purchase Agreement and as consideration for the transactions contemplated thereby, TDS paid to Seller approximately $125,000 in cash, subject to certain adjustments as forth in the PW Purchase Agreement. ​ (b) 2020 Credit Facility Payoff and Termination ​ Also on the Closing Date, the Company entered into an agreement with WAB with respect to the Company did not incur any prepayment or early termination penalties in connection with either the Repayment or the Termination. Upon the Termination and in connection with the Repayment Letter, all security interests and pledges granted to the secured parties thereunder were terminated and released. ​ (c) Rights Plan Adoption ​ On July 25, 2022, the Board approved and adopted a Rights Agreement, dated as of July 25, 2022 (the “Rights Agreement”), by and between the Company and American Stock Transfer & Trust Company, LLC, as Rights Agent (the “Rights Agent”). Pursuant to the Rights Agreement, the Board declared a dividend of one preferred share purchase right (each, a “Right”) for each outstanding share of common stock. The Rights are distributable to stockholders of record as of the close of business on August 5, 2022. See Exhibit 4.1 as filed with Form 8-K on July 26, 2022, incorporated by reference on this Quarterly Report on Form 10-Q, for additional information. ​ ​

Basis of Presentation, Summar_2

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements (Policies)	6 Months Ended
	Jun. 30, 2022
Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements
Basis of Presentation	(a) Basis of Presentation ​ The accompanying unaudited consolidated financial statements of the Company have been prepared in accordance with U.S. generally accepted accounting principles (“GAAP”) and applicable rules and regulations of the Securities and Exchange Commission (the “SEC”) regarding interim financial reporting. The unaudited interim consolidated financial statements have been prepared on the same basis as the annual audited consolidated financial statements and, in the opinion of management, reflect all adjustments (consisting of normal recurring accruals and adjustments) necessary to present fairly the Company’s interim consolidated financial position for the periods indicated. The interim results for the three and six months ended June 30, 2022 are not necessarily indicative of results to be expected for the year ending December 31, 2022, any other interim periods, or any future year or period. As such, the information included in this Quarterly Report on Form 10-Q should be read in conjunction with the audited consolidated financial statements and accompanying notes included in the Company’s Annual Report on Form 10-K filed with the SEC on February 25, 2022 (the “2021 Form 10-K”). ​ Except as described below, there have been no material changes to the Company’s significant accounting policies described in the 2021 Form 10-K that have a material impact on the Company’s accompanying unaudited consolidated financial statements and related notes.
Assets and Liabilities Held for Sale and Discontinued Operations	(b) Assets and Liabilities Held for Sale and Discontinued Operations ​ A long-lived asset (or disposal group) is classified as held for sale if its carrying amount will be recovered principally through a sale transaction rather than through continuing use and a sale is considered highly probable within a year. A long-lived asset (or disposal group) classified as held for sale is initially measured at the lower of its carrying amount or fair value less costs to sell. An impairment loss is recognized for any initial or subsequent write-down of the long-lived asset (or disposal group) to fair value less costs to sell. A gain or loss not previously recognized by the date of the sale of the long-lived asset (or disposal group) is recognized at the date of derecognition. ​ Long-lived assets (including those that are part of a disposal group) are not depreciated or amortized while they are classified as held for sale. Long-lived assets classified as held for sale and the assets of a disposal group classified as held for sale are presented separately from the other assets in the balance sheet. The liabilities of a disposal group classified as held for sale are presented separately from other liabilities in the balance sheet. ​ Unless otherwise noted, amounts and disclosures throughout the notes to the unaudited consolidated financial statements relate to the Company’s continuing operations. ​ Additional details surrounding the Company’s assets and liabilities held for sale and discontinued operations are included in Note 3.
Cloud Computing Arrangements	(c) Cloud Computing Arrangements ​ Costs to implement cloud computing arrangements that are hosted by third-party vendors are capitalized when incurred during the application development phase. Capitalized implementation costs are amortized on a straight-line basis over the reasonably certain term of the hosting arrangement, beginning when the service is ready for its intended use. As of June 30, 2022 and December 31, 2021, capitalized implementation costs of $1,045 and $747, respectively, were included in prepaid expenses, and $842 and $0, respectively, were included in other assets on the Company’s consolidated balance sheets. Accumulated amortization for these arrangements was $503 and $398 as of June 30, 2022 and December 31, 2021, respectively. Amortization expense for the three months ended June 30, 2022 and 2021, was $52 and $53, respectively. Amortization expense for the six months ended June 30, 2022 and 2021, was $105 and $103, respectively.
Vendor Financing Arrangements	(d) Vendor Financing Arrangements ​ On February 24, 2022, the Company expanded its existing relationship with a third-party service provider for business process outsourcing and technology services for its third-party administration services and electronic health records solutions. As a result, the third-party provider hired approximately 180 employees from the Company, hired to fill existing open positions and will augment with additional resources to meet client demand. The agreement term is seven years and includes total estimated fees of $115,300. ​ The arrangement includes extended payment terms for cloud computing implementation costs, internally developed software support, and business process support. In order to determine the present value of the commitment, the Company used an imputed interest rate of 9.5%, which is reflective of its estimated uncollateralized borrowing rate. As of June 30, 2022, the outstanding principal balance of the financing arrangement was $2,537 with an unamortized discount of $600, and was included in accrued expenses and other liabilities and other long-term liabilities on the Company’s consolidated balance sheet. Imputed interest expense from the arrangement was $30 and $36 for the three and six months ended June 30, 2022, respectively.
Concentration of Credit Risk	(e) Concentrations of Credit Risk ​ The Company’s medication fulfillment services clients are sponsors of the federal Medicare Part D plan (prescription drug coverage plan) and, therefore, subject to the payment regulations established by the Centers for Medicare & Medicaid Services (“CMS”). Under CMS guidelines, Medicare Part D sponsors are required to remit payment for claims within 14 ​ The Company’s clients also include health plans, pharmacies, and other healthcare providers. Credit associated with these accounts is extended based upon management’s evaluation of creditworthiness and is monitored on an on-going basis. ​ As of June 30, 2022 and December 31, 2021, no clients represented more than 10% of net accounts receivable. ​ One client accounted for 16% and 13% of total revenue for the three months ended June 30, 2022 and 2021, respectively, and 17% and 14% of total revenue for the six months ended June 30, 2022 and 2021, respectively. ​
Recent Accounting Pronouncements	(f) Recent Accounting Pronouncements In October 2021, the Financial Accounting Standards Board (“FASB”) issued Accounting Standards Update (“ASU”) 2021-08, Accounting for Contract Assets and Contract Liabilities from Contracts with Customers (“ASU 2021-08”). ASU 2021-08 requires an acquirer in a business combination to recognize and measure contract assets and contract liabilities from acquired contracts using the revenue recognition guidance under ASC Topic 606 (Revenue from Contracts with Customers) in order to align the recognition of a contract liability with the definition of performance obligation. This approach differs from the current requirement to measure contract assets and contract liabilities acquired in a business combination at fair value. ASU 2021-08 is effective for financial statements issued for fiscal years beginning after December 15, 2022; early adoption is permitted. The Company is currently evaluating the potential impact of the adoption of this standard on the Company’s consolidated financial statements.

Discontinued Operations (Tables

Discontinued Operations (Tables)	6 Months Ended
	Jun. 30, 2022
Discontinued Operations
Schedules of discontinued operations	The following table s ummarizes the results of operations of the businesses, which are included in loss from discontinued operations, net of tax in the consolidated statements of operations for the three and six months ended June 30, 2022 and 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended Six Months Ended ​ June 30, June 30, ​ 2022 2021 2022 2021 Revenue $ 16,961 ​ $ 18,012 ​ $ 33,456 ​ $ 35,914 Cost of revenue, exclusive of depreciation and amortization ​ 10,197 ​ ​ 9,643 ​ ​ 19,942 ​ ​ 19,691 Operating expenses ​ 8,761 ​ ​ 15,330 ​ ​ 22,354 ​ ​ 29,222 Impairment charges ​ 35,608 ​ ​ — ​ ​ 36,448 ​ ​ — Loss from discontinued operations before income taxes ​ (37,605) ​ ​ (6,961) ​ ​ (45,288) ​ ​ (12,999) Income tax (benefit) expense ​ (686) ​ ​ 52 ​ ​ (568) ​ ​ 130 Net loss from discontinued operations, net of tax $ (36,919) ​ $ (7,013) ​ $ (44,720) ​ $ (13,129) ​ The following table summarizes the current and noncurrent assets and liabilities classified as discontinued operations on the consolidated balance sheets as of June 30, 2022 and December 31, 2021: ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ 2022 2021 Cash $ 31 ​ $ 273 Accounts receivable, net ​ 10,748 ​ ​ 12,646 Prepaid expenses and other assets ​ 2,940 ​ ​ 1,592 Property and equipment, net ​ 1,707 ​ ​ — Operating lease right-of-use assets ​ 4,984 ​ ​ — Software development costs, net ​ 20,012 ​ ​ — Goodwill ​ 37,240 ​ ​ — Intangible assets, net ​ 104,138 ​ ​ — Impairment of carrying value ​ (18,176) ​ ​ — Total current assets of discontinued operations $ 163,624 ​ $ 14,511 ​ ​ ​ ​ ​ ​ Property and equipment, net $ — ​ $ 1,897 Operating lease right-of-use assets ​ — ​ ​ 4,730 Software development costs, net ​ — ​ ​ 15,940 Goodwill ​ — ​ ​ 55,512 Intangible assets, net ​ — ​ ​ 109,292 Other assets ​ — ​ ​ 187 Total noncurrent assets of discontinued operations $ — ​ $ 187,558 ​ ​ ​ ​ ​ ​ Operating lease liabilities $ 4,785 ​ $ 1,413 Accounts payable ​ 6,671 ​ ​ 4,308 Accrued expenses and other liabilities ​ 7,702 ​ ​ 6,659 Total current liabilities of discontinued operations $ 19,158 ​ $ 12,380 ​ ​ ​ ​ ​ ​ Noncurrent operating lease liabilities ​ — ​ $ 3,438 Other long-term liabilities ​ — ​ ​ 135 Total noncurrent liabilities of discontinued operations $ — ​ $ 3,573 The following table summarizes the significant operating non-cash items and investing activities of discontinued operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ ​ June 30, ​ 2022 2021 Depreciation and amortization ​ $ 7,331 ​ $ 13,463 Impairment charges ​ ​ 36,448 ​ ​ — Stock-based compensation ​ ​ 2,506 ​ ​ 3,752 Purchases of property and equipment ​ ​ (59) ​ ​ (230) Software development costs ​ ​ (6,006) ​ ​ (4,445)

Revenue (Tables)

Revenue (Tables)	6 Months Ended
	Jun. 30, 2022
Revenue.
Schedule of disaggregation of revenue	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ ​ ​ 2022 ​ ​ 2021 ​ ​ 2022 ​ ​ 2021 CareVention HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE product revenue ​ $ 55,892 ​ $ 46,858 ​ $ 106,865 ​ $ 88,700 PACE solutions ​ ​ 15,853 ​ ​ 14,347 ​ ​ 31,188 ​ ​ 28,266 ​ ​ $ 71,745 ​ $ 61,205 ​ $ 138,053 ​ $ 116,966 MedWise HealthCare: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Medication safety services ​ $ 774 ​ $ 3,037 ​ $ 1,493 ​ $ 5,997 Software subscription and services ​ ​ 78 ​ ​ 55 ​ ​ 161 ​ ​ 112 ​ ​ $ 852 ​ $ 3,092 ​ $ 1,654 ​ $ 6,109 Total revenue ​ $ 72,597 ​ $ 64,297 ​ $ 139,707 ​ $ 123,075
Schedule of contract assets and contract liabilities from contracts with customers	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ December 31, ​ ​ 2022 2021 Contract assets ​ $ 22,043 ​ $ 12,695 Contract liabilities ​ ​ 2,902 ​ ​ 2,191
Schedule of significant changes in the contract assets and the contract liabilities balances	​ ​ ​ ​ ​ ​ ​ June 30, ​ ​ 2022 Contract assets: ​ ​ ​ Contract assets, beginning of period ​ $ 12,695 Decreases due to cash received ​ ​ (10,627) Changes to the contract assets at the beginning of the period as a result of changes in estimates ​ ​ 2,915 Changes during the year, net of reclassifications to receivables ​ ​ 17,060 Contract assets, end of period ​ $ 22,043 ​ ​ ​ ​ Contract liabilities: ​ ​ ​ Contract liabilities, beginning of period ​ $ 2,191 Revenue recognized that was included in the contract liabilities balance at the beginning of the period ​ ​ (1,810) Increases due to cash received, excluding amounts recognized as revenue during the year ​ ​ 2,521 Contract liabilities, end of period ​ $ 2,902

Net Loss per Share (Tables)

Net Loss per Share (Tables)	6 Months Ended
	Jun. 30, 2022
Net Loss per Share
Schedule of calculation of basic and diluted net loss per share	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ 2022 2021 2022 2021 Numerator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss from continuing operations ​ $ (12,691) ​ $ (14,068) ​ $ (33,083) ​ $ (27,444) Net loss from discontinued operations ​ ​ (36,919) ​ ​ (7,013) ​ ​ (44,720) ​ ​ (13,129) Net loss ​ $ (49,610) ​ $ (21,081) ​ $ (77,803) ​ $ (40,573) Denominator (basic and diluted): ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted average shares of common stock outstanding, basic and diluted ​ ​ 23,959,726 ​ ​ 23,268,131 ​ ​ 23,913,050 ​ ​ 23,140,043 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss per share from continuing operations, basic and diluted ​ $ (0.53) ​ $ (0.60) ​ $ (1.38) ​ $ (1.19) Net loss per share from discontinued operations, basic and diluted ​ ​ (1.54) ​ ​ (0.31) ​ ​ (1.87) ​ ​ (0.56) Total net loss per share, basic and diluted ​ $ (2.07) ​ $ (0.91) ​ $ (3.25) ​ $ (1.75)
Schedule of shares excluded from the calculation of diluted net loss per share attributable to common stockholders	​ ​ ​ ​ ​ ​ ​ ​ June 30, ​ 2022 2021 Stock options to purchase common stock ​ 1,448,537 ​ 1,741,465 Unvested restricted stock and restricted stock units ​ 2,324,497 ​ 1,658,481 Common stock warrants ​ 4,646,393 ​ 4,646,393 Conversion of convertible senior subordinated notes ​ 4,646,393 ​ 4,646,393 ​ ​ 13,065,820 ​ 12,692,732

Other Current Assets (Tables)

Other Current Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Other Current Assets
Schedule of Other Current Assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 December 31, 2021 Contract assets ​ $ 22,043 ​ $ 12,695 Non-trade receivables ​ ​ 778 ​ ​ 3,289 Other ​ ​ 2,200 ​ ​ 2,049 Total other current assets ​ $ 25,021 ​ $ 18,033

Software Development Costs (Tab

Software Development Costs (Tables)	6 Months Ended
	Jun. 30, 2022
Software Development Costs
Schedule of capitalized software costs	​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 December 31, 2021 Software development costs $ 46,750 ​ $ 49,481 Less: accumulated amortization ​ (15,475) ​ ​ (20,227) Software development costs, net $ 31,275 ​ $ 29,254 ​ ​ ​ ​ ​ ​ Capitalized software development costs included above not yet subject to amortization $ 8,379 ​ $ 5,328

Goodwill and Intangible Assets

Goodwill and Intangible Assets (Tables)	6 Months Ended
	Jun. 30, 2022
Goodwill and Intangible Assets
Schedule of intangible assets	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 2.9 ​ $ 1,340 ​ $ (939) ​ $ 401 Client relationships ​ 11.7 ​ ​ 51,264 ​ ​ (13,306) ​ ​ 37,958 Non-competition agreements ​ 5.0 ​ ​ 1,640 ​ ​ (1,139) ​ ​ 501 Developed technology ​ 6.2 ​ ​ 14,720 ​ ​ (11,640) ​ ​ 3,080 Domain name ​ 10.0 ​ ​ 59 ​ ​ (29) ​ ​ 30 Total intangible assets ​ ​ ​ $ 69,023 ​ $ (27,053) ​ $ 41,970 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted Average ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Amortization Period ​ ​ ​ ​ Accumulated ​ Intangible ​ (in years) Gross Value Amortization Assets, net December 31, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Trade names ​ 2.9 ​ $ 1,340 ​ $ (853) ​ $ 487 Client relationships ​ 11.7 ​ ​ 51,264 ​ ​ (11,042) ​ ​ 40,222 Non-competition agreements ​ 5.0 ​ ​ 1,640 ​ ​ (975) ​ ​ 665 Developed technology ​ 6.2 ​ ​ 14,720 ​ ​ (10,768) ​ ​ 3,952 Domain name ​ 10.0 ​ ​ 59 ​ ​ (27) ​ ​ 32 Total intangible assets ​ ​ ​ $ 69,023 ​ $ (23,665) ​ $ 45,358
Schedule of estimated amortization expense	​ ​ ​ ​ ​ Years Ending December 31, ​ ​ 2022 (July 1 – December 31) ​ $ 3,363 2023 ​ ​ 6,162 2024 ​ ​ 4,684 2025 ​ ​ 4,466 2026 ​ ​ 4,338 2027 ​ ​ 4,271 Thereafter ​ ​ 14,686 Total estimated amortization expense ​ $ 41,970

Accrued Expenses and Other Li_2

Accrued Expenses and Other Liabilities (Tables)	6 Months Ended
	Jun. 30, 2022
Accrued Expenses and Other Liabilities
Schedule of accrued expenses and other liabilities	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 December 31, 2021 Employee related expenses ​ $ 5,442 ​ $ 8,595 Contract liability ​ ​ 2,751 ​ ​ 2,015 Customer deposits ​ ​ 904 ​ ​ 904 Client funds obligations* ​ ​ 7,062 ​ ​ 6,038 Contract labor ​ ​ 2,331 ​ ​ 838 Interest ​ ​ 2,340 ​ ​ 2,281 Vendor financing arrangements ​ ​ 96 ​ ​ — Professional fees ​ ​ 1,438 ​ ​ 1,327 Consideration payable to customer ​ ​ 24,587 ​ ​ 15,971 Income and non-income taxes payable ​ ​ 45 ​ ​ 15 Other expenses ​ ​ 3,183 ​ ​ 3,013 Total accrued expenses and other liabilities ​ $ 50,179 ​ $ 40,997 ​ *This amount represents client funds held by the Company, with an offsetting amount included in restricted cash.

Lines of Credit and Long-Term_2

Lines of Credit and Long-Term Debt (Tables)	6 Months Ended
	Jun. 30, 2022
Lines of Credit and Long-Term Debt
Schedule of long-term debt obligations	​ ​ ​ ​ ​ ​ ​ ​ ​ June 30, 2022 December 31, 2021 Convertible senior subordinated notes ​ $ 235,272 ​ $ 325,000 Convertible senior subordinated notes - related party ​ ​ 89,728 ​ ​ — Unamortized discount, including debt issuance costs, on convertible senior subordinated notes ​ ​ (5,037) ​ ​ (5,701) Total long-term debt, net ​ $ 319,963 ​ $ 319,299

Stock-Based Compensation (Table

Stock-Based Compensation (Tables)	6 Months Ended
	Jun. 30, 2022
Stock-Based Compensation
Summary of restricted stock award activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ average ​ ​ Number ​ grant-date ​ of shares fair value Outstanding at December 31, 2021 ​ 2,196,566 ​ $ 40.19 Granted ​ 768,351 ​ ​ 5.32 Vested ​ (456,774) ​ ​ 44.01 Forfeited ​ (169,424) ​ ​ 36.67 Outstanding at June 30, 2022 ​ 2,338,719 ​ $ 28.24
Schedule of weighted average assumptions for employee grants	​ ​ ​ ​ ​ ​ ​ Six Months Ended ​ Valuation assumptions: June 30, 2021 ​ Expected volatility ​ 58.57 % Expected term (years) ​ 5.48 ​ Risk-free interest rate ​ 0.50 % Dividend yield ​ — ​
Summary of stock option activity	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Weighted ​ ​ ​ ​ ​ ​ ​ Weighted ​ average ​ ​ ​ ​ ​ ​ ​ average ​ remaining ​ Aggregate ​ ​ Number ​ exercise ​ contractual ​ intrinsic ​ of shares price term value Outstanding at December 31, 2021 ​ 1,604,226 ​ $ 29.90 ​ ​ ​ ​ Exercised ​ (12,573) ​ ​ 5.01 ​ ​ ​ ​ ​ Forfeited ​ (143,116) ​ ​ 46.27 ​ ​ ​ ​ ​ Outstanding at June 30, 2022 ​ 1,448,537 ​ $ 28.49 ​ 4.9 ​ $ - Options vested and expected to vest at June 30, 2022 ​ 1,448,537 ​ $ 28.49 ​ 4.9 ​ $ - Exercisable at June 30, 2022 ​ 1,379,541 ​ $ 27.16 ​ 4.8 ​ $ -
Schedule of recorded stock-based compensation expense related to stock options	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended ​ Six Months Ended ​ ​ June 30, ​ June 30, ​ 2022 2021 2022 2021 Cost of revenue - product ​ $ 223 ​ $ 337 ​ $ 447 ​ $ 596 Cost of revenue - service ​ ​ 570 ​ ​ 898 ​ ​ 1,471 ​ ​ 1,748 Research and development ​ ​ 761 ​ ​ 2,069 ​ ​ 2,280 ​ ​ 3,272 Sales and marketing ​ ​ 50 ​ ​ 345 ​ ​ 308 ​ ​ 1,042 General and administrative ​ ​ 3,488 ​ ​ 6,178 ​ ​ 8,289 ​ ​ 10,541 Discontinued operations ​ ​ 1,600 ​ ​ 2,522 ​ ​ 2,506 ​ ​ 3,752 Total stock-based compensation expense ​ $ 6,692 ​ $ 12,349 ​ $ 15,301 ​ $ 20,951

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2022
Fair Value Measurements
Schedule of carrying value and fair value of financial instruments	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Face Value Carrying Value Fair Value 1.75% Convertible Senior Subordinated Notes due 2026 ​ $ 325,000 ​ $ 319,963 ​ $ 219,193

Segment Reporting (Tables)

Segment Reporting (Tables)	6 Months Ended
	Jun. 30, 2022
Segment Reporting
Schedule of reportable operating segment information	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ Shared Services and Other ​ Consolidated Revenue: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 55,892 ​ $ — ​ $ 55,892 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 15,853 ​ ​ — ​ ​ 15,853 Medication safety services ​ ​ — ​ ​ 774 ​ ​ 774 Software subscription and services ​ ​ — ​ ​ 78 ​ ​ 78 Total service revenue ​ ​ 15,853 ​ ​ 852 ​ ​ 16,705 Total revenue ​ $ 71,745 ​ $ 852 ​ $ 72,597 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 46,858 ​ $ — ​ $ 46,858 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 14,347 ​ ​ — ​ ​ 14,347 Medication safety services ​ ​ — ​ ​ 3,037 ​ ​ 3,037 Software subscription and services ​ ​ — ​ ​ 55 ​ ​ 55 Total service revenue ​ ​ 14,347 ​ ​ 3,092 ​ ​ 17,439 Total revenue ​ $ 61,205 ​ $ 3,092 ​ $ 64,297 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 106,865 ​ $ — ​ $ 106,865 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 31,188 ​ ​ — ​ ​ 31,188 Medication safety services ​ ​ — ​ ​ 1,493 ​ ​ 1,493 Software subscription and services ​ ​ — ​ ​ 161 ​ ​ 161 Total service revenue ​ ​ 31,188 ​ ​ 1,654 ​ ​ 32,842 Total revenue ​ $ 138,053 ​ $ 1,654 ​ $ 139,707 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Product revenue ​ $ 88,700 ​ $ — ​ $ 88,700 Service revenue ​ ​ ​ ​ ​ ​ ​ ​ ​ PACE solutions ​ ​ 28,266 ​ ​ — ​ ​ 28,266 Medication safety services ​ ​ — ​ ​ 5,997 ​ ​ 5,997 Software subscription and services ​ ​ — ​ ​ 112 ​ ​ 112 Total service revenue ​ ​ 28,266 ​ ​ 6,109 ​ ​ 34,375 Total revenue ​ $ 116,966 ​ $ 6,109 ​ $ 123,075 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ CareVention HealthCare ​ Shared Services and Other ​ Consolidated Adjusted EBITDA (loss) from Continuing Operations: ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 13,396 ​ $ (11,339) ​ $ 2,057 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 14,059 ​ $ (10,796) ​ $ 3,263 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2022 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 25,480 ​ $ (22,341) ​ $ 3,139 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Six Months Ended June 30, 2021 ​ ​ ​ ​ ​ ​ ​ ​ ​ Adjusted EBITDA (loss) ​ $ 26,969 ​ $ (22,123) ​ $ 4,846
Schedules of reconciliation of net loss to Adjusted EBITDA	​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ 2022 2021 2022 2021 Reconciliation of Net Loss to Adjusted EBITDA from Continuing Operations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss ​ $ (49,610) ​ $ (21,081) ​ $ (77,803) ​ $ (40,573) Add: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Interest expense, net ​ ​ 2,444 ​ ​ 2,182 ​ ​ 4,713 ​ ​ 4,729 Income tax expense ​ ​ 159 ​ ​ 81 ​ ​ 375 ​ ​ 202 Depreciation and amortization ​ ​ 5,489 ​ ​ 4,980 ​ ​ 11,231 ​ ​ 9,781 Impairment charges ​ ​ — ​ ​ — ​ ​ 4,062 ​ ​ — Business optimization expenses ​ ​ — ​ ​ — ​ ​ 787 ​ ​ — Severance costs ​ ​ — ​ ​ 162 ​ ​ 575 ​ ​ 162 Executive transition ​ ​ 150 ​ ​ — ​ ​ 150 ​ ​ — Divestiture-related expense ​ ​ 1,414 ​ ​ — ​ ​ 1,534 ​ ​ — Acquisition-related expense ​ ​ — ​ ​ 99 ​ ​ — ​ ​ 217 Stock-based compensation expense ​ ​ 5,092 ​ ​ 9,827 ​ ​ 12,795 ​ ​ 17,199 Loss from discontinued operations ​ ​ 36,919 ​ ​ 7,013 ​ ​ 44,720 ​ ​ 13,129 Adjusted EBITDA from continuing operations ​ $ 2,057 ​ $ 3,263 ​ $ 3,139 ​ $ 4,846 Adjusted EBITDA from discontinued operations ​ ​ 1,117 ​ ​ 2,700 ​ ​ 2,557 ​ ​ 4,716 Total Adjusted EBITDA ​ $ 3,174 ​ $ 5,963 ​ $ 5,696 ​ $ 9,562 ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Three Months Ended June 30, ​ Six Months Ended June 30, ​ ​ 2022 2021 2022 2021 Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Net loss from discontinued operations, net of tax ​ $ (36,919) ​ $ (7,013) ​ $ (44,720) ​ $ (13,129) Add: ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ ​ Income tax (benefit) expense ​ ​ (686) ​ ​ 52 ​ ​ (568) ​ ​ 130 Depreciation and amortization ​ ​ — ​ ​ 6,639 ​ ​ 7,331 ​ ​ 13,463 Impairment charges ​ ​ 35,608 ​ ​ — ​ ​ 36,448 ​ ​ — Settlement ​ ​ 1,448 ​ ​ 500 ​ ​ 1,448 ​ ​ 500 Divestiture-related expense ​ ​ 66 ​ ​ — ​ ​ 112 ​ ​ — Stock-based compensation expense ​ ​ 1,600 ​ ​ 2,522 ​ ​ 2,506 ​ ​ 3,752 Adjusted EBITDA from discontinued operations ​ $ 1,117 ​ $ 2,700 ​ $ 2,557 ​ $ 4,716

Basis of Presentation, Summar_3

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements - Cloud Computing Arrangements (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Other assets
Accumulated amortization, cloud computing implementation costs	$ 503		$ 503		$ 398
Amortization expense, cloud computing implementation costs	52	$ 53	105	$ 103
Prepaid expenses
Other assets
Capitalized cloud computing implementation costs	1,045		1,045		747
Other assets
Other assets
Capitalized cloud computing implementation costs	$ 842		$ 842		$ 0

Basis of Presentation, Summar_4

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements - Vendor Financing Arrangements (Details) - Business process support and technology services partner $ in Thousands		3 Months Ended	6 Months Ended
	Feb. 24, 2022 USD ($) employee	Jun. 30, 2022 USD ($)	Jun. 30, 2022 USD ($)
Financing Arrangements
Number of Company employees hired by third-party provider. | employee	180
Term of business partnership agreement.	7 years
Total estimated fees under business partnership agreement	$ 115,300
Vendor Financing Arrangements, Imputed interest rate (as a percent)	9.50%
Vendor Financing Arrangements, Non-cash interest expense		$ 30	$ 36
Accrued expenses and other liabilities, Current and noncurrent
Financing Arrangements
Vendor Financing Arrangements, Outstanding principal balance		2,537	2,537
Vendor Financing Arrangements, Unamortized discount		$ 600	$ 600

Basis of Presentation, Summar_5

Basis of Presentation, Summary of Significant Accounting Policies, and Recent Accounting Pronouncements - Concentrations (Details) - customer	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Concentration Risk
Electronic payment term of claims			14 days
Nonelectronic payment term of claims			30 days
Revenue | Customer risk | Client One
Concentration Risk
Number of customers	1	1	1	1
Concentration risk (as a percent)	16%	13%	17%	14%

Discontinued Operations - Summa

Discontinued Operations - Summary (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2022	Aug. 01, 2022	Jun. 18, 2022
DoseMe, SinfonaRx and PrescribeWellness businesses | Discontinued Operations, Held-for-sale
Discontinued Operations
Goodwill impairment		$ 18,272
Impairment charge on net assets held for sale	$ 18,076	18,176
Impairment charges	35,608	$ 36,448
PrescribeWellness business | Discontinued Operations, Held-for-sale
Discontinued Operations
Consideration to be received at closing				$ 125,000
Contingent consideration				15,000
PrescribeWellness business | Discontinued Operations, Held-for-sale | Maximum
Discontinued Operations
Cash consideration				$ 140,000
PrescribeWellness business | Discontinued Operations, Disposed of by Sale | Subsequent Event.
Discontinued Operations
Consideration to be received at closing			$ 125,000
DoseMe and SinfonaRx businesses
Discontinued Operations
Period within which sale is highly probable		1 year
SinfonaRx and PrescribeWellness businesses | Discontinued Operations, Held-for-sale
Discontinued Operations
Goodwill impairment	$ 17,532

Discontinued Operations - Resul

Discontinued Operations - Results of Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Loss from discontinued operations
Net loss from discontinued operations, net of tax	$ (36,919)	$ (7,013)	$ (44,720)	$ (13,129)
DoseMe, SinfonaRx and PrescribeWellness businesses | Discontinued Operations, Held-for-sale
Loss from discontinued operations
Revenue	16,961	18,012	33,456	35,914
Cost of revenue, exclusive of depreciation and amortization	10,197	9,643	19,942	19,691
Operating expenses	8,761	15,330	22,354	29,222
Impairment charges	35,608		36,448
Loss from discontinued operations before income taxes	(37,605)	(6,961)	(45,288)	(12,999)
Income tax (benefit) expense	(686)	52	(568)	130
Net loss from discontinued operations, net of tax	$ (36,919)	$ (7,013)	$ (44,720)	$ (13,129)

Discontinued Operations - Asset

Discontinued Operations - Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Current assets of discontinued operations
Total current assets of discontinued operations	$ 163,624	$ 14,511
Noncurrent assets of discontinued operations
Total noncurrent assets of discontinued operations		187,558
Current liabilities of discontinued operations
Total current liabilities of discontinued operations	19,158	12,380
Noncurrent liabilities of discontinued operations
Total noncurrent liabilities of discontinued operations		3,573
DoseMe, SinfonaRx and PrescribeWellness businesses | Discontinued Operations, Held-for-sale
Current assets of discontinued operations
Cash	31	273
Accounts receivable, net	10,748	12,646
Prepaid expenses and other assets	2,940	1,592
Property and equipment, net	1,707
Operating lease right-of-use assets	4,984
Software development costs, net	20,012
Goodwill	37,240
Intangible assets, net	104,138
Impairment of carrying value	(18,176)
Total current assets of discontinued operations	163,624	14,511
Noncurrent assets of discontinued operations
Property and equipment, net		1,897
Operating lease right-of-use assets		4,730
Software development costs, net		15,940
Goodwill		55,512
Intangible assets, net		109,292
Other assets		187
Total noncurrent assets of discontinued operations		187,558
Current liabilities of discontinued operations
Operating lease liabilities	4,785	1,413
Accounts payable	6,671	4,308
Accrued expenses and other liabilities	7,702	6,659
Total current liabilities of discontinued operations	$ 19,158	12,380
Noncurrent liabilities of discontinued operations
Noncurrent operating lease liabilities		3,438
Other long-term liabilities		135
Total noncurrent liabilities of discontinued operations		$ 3,573

Discontinued Operations - Opera

Discontinued Operations - Operating non-cash items and investing activities (Details) - DoseMe, SinfonaRx and PrescribeWellness businesses - Discontinued Operations, Held-for-sale - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Operating non-cash items and investing activities of discontinued operations:
Depreciation and amortization		$ 6,639	$ 7,331	$ 13,463
Impairment charges	$ 35,608		36,448
Stock-based compensation			2,506	3,752
Purchases of property and equipment			(59)	(230)
Software development costs			$ (6,006)	$ (4,445)

Revenue - General (Details)

Revenue - General (Details)	6 Months Ended
	Jun. 30, 2022
Minimum
Contract with customer
Client contract term	1 year
Termination notice period	0 days
Maximum
Contract with customer
Client contract term	5 years
Termination notice period	180 days

Revenue - Disaggregation (Detai

Revenue - Disaggregation (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Disaggregation of revenue
Total revenue	$ 72,597	$ 64,297	$ 139,707	$ 123,075
Product
Disaggregation of revenue
Total revenue	55,892	46,858	106,865	88,700
Service
Disaggregation of revenue
Total revenue	16,705	17,439	32,842	34,375
Service - PACE solutions
Disaggregation of revenue
Total revenue	15,853	14,347	31,188	28,266
Service - Medication safety services
Disaggregation of revenue
Total revenue	774	3,037	1,493	5,997
Service - Software subscription and services
Disaggregation of revenue
Total revenue	78	55	161	112
CareVention HealthCare
Disaggregation of revenue
Total revenue	71,745	61,205	138,053	116,966
CareVention HealthCare | Product
Disaggregation of revenue
Total revenue	55,892	46,858	106,865	88,700
CareVention HealthCare | PACE product revenue
Disaggregation of revenue
Total revenue	55,892	46,858	106,865	88,700
CareVention HealthCare | Service
Disaggregation of revenue
Total revenue	15,853	14,347	31,188	28,266
CareVention HealthCare | Service - PACE solutions
Disaggregation of revenue
Total revenue	15,853	14,347	31,188	28,266
MedWise HealthCare
Disaggregation of revenue
Total revenue	852	3,092	1,654	6,109
MedWise HealthCare | Service - Medication safety services
Disaggregation of revenue
Total revenue	774	3,037	1,493	5,997
MedWise HealthCare | Service - Software subscription and services
Disaggregation of revenue
Total revenue	$ 78	$ 55	$ 161	$ 112

Revenue - Contract Balances (De

Revenue - Contract Balances (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021	Dec. 31, 2020
Contract Balances
Contract assets	$ 22,043	$ 12,695
Contract liabilities	$ 2,902	$ 2,191	$ 1,982

Revenue - Change in contract ba

Revenue - Change in contract balances (Details) - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Contract assets:
Contract assets, beginning of period	$ 12,695
Decreases due to cash received	(10,627)
Changes to the contract assets at the beginning of the period as a result of changes in estimates	2,915
Changes during the year, net of reclassifications to receivables	17,060
Contract assets, end of period	22,043
Contract liabilities:
Contract liabilities, beginning of period	2,191	$ 1,982
Revenue recognized that was included in the contract liabilities balance at the beginning of the period	(1,810)	$ (1,243)
Increases due to cash received, excluding amounts recognized as revenue during the period	2,521
Contract liabilities, end of period	$ 2,902

Net Loss per Share - EPS (Detai

Net Loss per Share - EPS (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Numerator (basic and diluted):
Net loss from continuing operations, basic	$ (12,691)	$ (14,068)	$ (33,083)	$ (27,444)
Net loss from discontinued operations, basic	(36,919)	(7,013)	(44,720)	(13,129)
Net loss, basic	(49,610)	(21,081)	(77,803)	(40,573)
Net loss from continuing operations, diluted	(12,691)	(14,068)	(33,083)	(27,444)
Net loss from discontinued operations, diluted	(36,919)	(7,013)	(44,720)	(13,129)
Net loss, diluted	$ (49,610)	$ (21,081)	$ (77,803)	$ (40,573)
Denominator (basic and diluted):
Weighted average common shares outstanding, basic (in shares)	23,959,726	23,268,131	23,913,050	23,140,043
Weighted average common shares outstanding, diluted (in shares)	23,959,726	23,268,131	23,913,050	23,140,043
Net loss per share from continuing operations, basic (in dollars per share)	$ (0.53)	$ (0.60)	$ (1.38)	$ (1.19)
Net loss per share from discontinued operations, basic (in dollars per share)	(1.54)	(0.31)	(1.87)	(0.56)
Total net loss per share, basic (in dollars per share)	(2.07)	(0.91)	(3.25)	(1.75)
Net loss per share from continuing operations, diluted (in dollars per share)	(0.53)	(0.60)	(1.38)	(1.19)
Net loss per share from discontinued operations, diluted (in dollars per share)	(1.54)	(0.31)	(1.87)	(0.56)
Total net loss per share, diluted (in dollars per share)	$ (2.07)	$ (0.91)	$ (3.25)	$ (1.75)

Net Loss per Share - Anti-dilut

Net Loss per Share - Anti-dilutive Securities (Details) - shares	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	13,065,820	12,692,732
Stock options
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	1,448,537	1,741,465
Restricted stock and restricted stock units
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	2,324,497	1,658,481
Common stock warrants/Convertible note warrants
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	4,646,393	4,646,393
Conversion of convertible senior subordinated notes
Securities excluded from the calculation of diluted net loss per share attributable to common stockholders
Amount of antidilutive securities excluded from computation of earnings per share	4,646,393	4,646,393

Other Current Assets (Details)

Other Current Assets (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Other Current Assets
Contract assets	$ 22,043	$ 12,695
Non-trade receivables	778	3,289
Other	2,200	2,049
Total other current assets	$ 25,021	$ 18,033

Property and Equipment (Details

Property and Equipment (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Property and Equipment
Property and equipment, net	$ 10,126		$ 10,126		$ 11,778
Depreciation and amortization	5,489	$ 4,980	11,231	$ 9,781
Property and equipment
Property and Equipment
Accumulated depreciation	18,131		18,131		$ 17,427
Depreciation and amortization	$ 1,214	$ 900	$ 2,061	$ 1,847

Software Development Costs (Det

Software Development Costs (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Software Development Costs
Software development costs	$ 46,750		$ 46,750		$ 49,481
Less: accumulated amortization	(15,475)		(15,475)		(20,227)
Software development costs, net	31,275		31,275		29,254
Capitalized software development costs included above not yet subject to amortization	8,379		8,379		$ 5,328
Amortization expense	$ 2,581	$ 2,165	5,781	$ 4,103
Long-lived asset impairment charge			$ 4,062

Goodwill and Intangible Asset_2

Goodwill and Intangible Assets - Goodwill (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Goodwill and related changes
Goodwill	$ 115,323	$ 115,323

Goodwill and Intangible Asset_3

Goodwill and Intangible Assets - Intangible assets (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Intangible Assets
Gross Value	$ 69,023		$ 69,023		$ 69,023
Accumulated Amortization	(27,053)		(27,053)		(23,665)
Intangible Assets, net	41,970		41,970		$ 45,358
Amortization expense	1,695	$ 1,915	$ 3,389	$ 3,831
Trade name
Intangible Assets
Weighted Average Amortization Period			2 years 10 months 24 days		2 years 10 months 24 days
Gross Value	1,340		$ 1,340		$ 1,340
Accumulated Amortization	(939)		(939)		(853)
Intangible Assets, net	401		$ 401		$ 487
Client relationships
Intangible Assets
Weighted Average Amortization Period			11 years 8 months 12 days		11 years 8 months 12 days
Gross Value	51,264		$ 51,264		$ 51,264
Accumulated Amortization	(13,306)		(13,306)		(11,042)
Intangible Assets, net	37,958		$ 37,958		$ 40,222
Non-competition agreements
Intangible Assets
Weighted Average Amortization Period			5 years		5 years
Gross Value	1,640		$ 1,640		$ 1,640
Accumulated Amortization	(1,139)		(1,139)		(975)
Intangible Assets, net	501		$ 501		$ 665
Developed technology
Intangible Assets
Weighted Average Amortization Period			6 years 2 months 12 days		6 years 2 months 12 days
Gross Value	14,720		$ 14,720		$ 14,720
Accumulated Amortization	(11,640)		(11,640)		(10,768)
Intangible Assets, net	3,080		$ 3,080		$ 3,952
Domain name
Intangible Assets
Weighted Average Amortization Period			10 years		10 years
Gross Value	59		$ 59		$ 59
Accumulated Amortization	(29)		(29)		(27)
Intangible Assets, net	$ 30		$ 30		$ 32

Goodwill and Intangible Asset_4

Goodwill and Intangible Assets - Amortization (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Estimated amortization expense
2022 (July 1 - December 31)	$ 3,363
2023	6,162
2024	4,684
2025	4,466
2026	4,338
2027	4,271
Thereafter	14,686
Total estimated amortization expense	$ 41,970	$ 45,358

Accrued Expenses and Other Li_3

Accrued Expenses and Other Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Accrued Expenses and Other Liabilities
Employee related expenses	$ 5,442	$ 8,595
Contract liability	2,751	2,015
Customer deposits	904	904
Client funds obligations	7,062	6,038
Contract labor	2,331	838
Interest	2,340	2,281
Vendor financing arrangements	96
Professional fees	1,438	1,327
Consideration payable to customer	24,587	15,971
Income and non-income taxes payable	45	15
Other expenses	3,183	3,013
Total accrued expenses and other liabilities	$ 50,179	$ 40,997

Lines of Credit and Long-Term_3

Lines of Credit and Long-Term Debt - Lines of Credit (Details) - 2020 Credit Facility - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Dec. 18, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Lines of Credit
Maximum borrowing capacity	$ 120,000
Sublimit of loan	1,000
Amount available to be maintained for draw	$ 10,000
Factor multiplied with trailing twelve months EBITDA to determine available borrowing	3
Trailing period	12 months
Commitment fee at closing (as a percent)	0.50%
Commitment fee payable on each anniversary (as a percent)	0.25%
Aggregate borrowings outstanding		$ 57,200		$ 57,200
Letter of credit outstanding		$ 100		$ 100
Interest rate (as a percent)		4.37%	3.34%	4.37%	3.34%
Effective rate, unused line fee (as a percent)		0.35%	0.45%	0.35%	0.45%
Interest expense		$ 637	$ 267	$ 1,097	$ 528
Deferred financing costs, gross		1,534		1,534
Amortization of deferred financing costs to interest expense		138	$ 135	275	$ 268
Deferred financing costs, net		$ 699		$ 699		$ 624
Maximum
Lines of Credit
Leverage ratio	3
LIBOR
Lines of Credit
Spread on variable rate (as a percent)	3.25%

Lines of Credit and Long-Term_4

Lines of Credit and Long-Term Debt - Convertible Senior Subordinated Notes (Details) $ / shares in Units, $ in Thousands		3 Months Ended		6 Months Ended
	Feb. 12, 2019 USD ($) D $ / shares	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)	Jan. 01, 2021
Lines of Credit and Long-Term Debt
Accrued interest payable		$ 2,340		$ 2,340		$ 2,281
Cash paid for interest				3,882	$ 3,398
Long term debt, net		319,963		319,963		$ 319,299
2026 Notes, Convertible Senior Subordinated Notes
Lines of Credit and Long-Term Debt
Aggregate borrowings	$ 325,000	$ 325,000		$ 325,000
Interest rate (as a percent)	1.75%	1.75%		1.75%
Initial conversion rate	0.0142966
Initial conversion price (in dollars per share) | $ / shares	$ 69.95
Principal amount	$ 1
Debt issuance costs	$ 9,372
Effective interest rate							2.20%
Interest expense		$ 1,755	$ 1,747	$ 3,508	3,493
Paid or accrued interest		1,422	1,421	2,844	2,843
Non-cash accretion of discounts		333	326	664	650
Amount of additional interest payable			$ 212		$ 212
Accrued interest payable		2,133		2,133
Long term debt, net		$ 319,963		$ 319,963
2026 Notes, Convertible Senior Subordinated Notes | Debt Conversion Scenario One
Lines of Credit and Long-Term Debt
Trading days | D	20
Consecutive trading days | D	30
Stock price trigger percentage (as a percent)	130%
2026 Notes, Convertible Senior Subordinated Notes | Debt Conversion Scenario Two
Lines of Credit and Long-Term Debt
Trading days | D	5
Consecutive trading days | D	5
Principal amount	$ 1
Stock price trigger percentage (as a percent)	98%

Lines of Credit and Long-Term_5

Lines of Credit and Long-Term Debt - Convertible Note Hedge and Warrant Transactions (Details) - USD ($) $ / shares in Units, $ in Thousands		6 Months Ended
	Feb. 12, 2019	Jun. 30, 2022
Warrants and options indexed to Company's stock
Warrants exercised		0
Option indexed to own shares, convertible senior subordinated notes
Warrants and options indexed to Company's stock
Options indexed to Company's stock (in shares)	4,646,393
Price of options indexed to Company's stock (in dollars per share)	$ 105.58
Proceeds from sale of warrants	$ 65,910
Common stock warrants/Convertible note warrants
Warrants and options indexed to Company's stock
Option to purchase	4,646,393
Exercise price (in dollars per share)	$ 69.95
Premiums paid for the note hedges	$ 101,660

Lines of Credit and Long-Term_6

Lines of Credit and Long-Term Debt - Long-term debt (Details) - USD ($) $ in Thousands	Jun. 30, 2022	Dec. 31, 2021
Long-Term Debt
Unamortized discount, including debt issuance costs, on convertible senior subordinated notes	$ (5,037)	$ (5,701)
Total long-term debt, net	319,963	319,299
2026 Notes, Convertible Senior Subordinated Notes
Long-Term Debt
Total long-term debt, net	319,963
Convertible senior subordinated notes - excluding related party
Long-Term Debt
Convertible senior subordinated notes	235,272	$ 325,000
Convertible senior subordinated notes - related party
Long-Term Debt
Convertible senior subordinated notes	$ 89,728

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Thousands		3 Months Ended		6 Months Ended
	Feb. 12, 2021	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Income Taxes
Income tax expense		$ 159	$ 81	$ 375	$ 202
Effective tax rate (as a percent)		(1.30%)	(0.60%)	(1.10%)	(0.70%)
Increase in deferred tax asset	$ 26,313
Increase (decrease) valuation allowance	$ 26,313

Stock-Based Compensation - Plan

Stock-Based Compensation - Plans (Details) - 2016 Plan - shares		1 Months Ended
	Feb. 25, 2022	Sep. 30, 2016	Jun. 30, 2022
Stock-Based Compensation
Automatic increase on share reserve (as a percent)		5%
Additional shares authorized	1,283,321
Available for future grant (in shares)			1,817,777

Stock-Based Compensation - Rest

Stock-Based Compensation - Restricted Common Stock and Restricted Stock Units (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Weighted average grant date fair value
Stock-based compensation expense, including discontinued operations (in dollars)	$ 6,692	$ 12,349	$ 15,301	$ 20,951
Restricted stock and restricted stock units
Weighted average grant date fair value
Stock-based compensation expense, including discontinued operations (in dollars)	5,681	$ 10,124	13,068	$ 16,399
Unrecognized compensation expense (in dollars)	$ 44,394		$ 44,394
Weighted average period expected to be recognized			2 years 4 months 24 days
Restricted stock and restricted stock units | Minimum
Stock-Based Compensation
Vesting period			1 year
Restricted stock and restricted stock units | Maximum
Stock-Based Compensation
Vesting period			4 years
Restricted stock, performance based restricted stock and restricted stock units
Number of shares
Outstanding at beginning of period (in shares)			2,196,566
Granted (in shares)			768,351
Vested (in shares)			(456,774)
Forfeited (in shares)			(169,424)
Outstanding at end of period (in shares)	2,338,719		2,338,719
Weighted average grant date fair value
Outstanding at beginning of period (in dollars per share)			$ 40.19
Granted (in dollars per share)			5.32
Vested (in dollars per share)			44.01
Forfeited (in dollars per share)			36.67
Outstanding at end of period (in dollars per share)	$ 28.24		$ 28.24
Restricted stock units
Weighted average grant date fair value
Awards vested but not yet issued	14,222		14,222

Stock-Based Compensation - Perf

Stock-Based Compensation - Performance Based Equity Awards (Details) - USD ($) $ / shares in Units, $ in Thousands						3 Months Ended		6 Months Ended
	Dec. 31, 2021	Apr. 30, 2021	Apr. 27, 2021	Oct. 29, 2020	May 04, 2020	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Stock-Based Compensation
Stock-based compensation expense, including discontinued operations (in dollars)						$ 6,692	$ 12,349	$ 15,301	$ 20,951
Performance stock units | Award Date, May 4, 2020
Stock-Based Compensation
Granted (in shares)					10,686
Vesting period					2 years
Weighted average grant-date fair value (in dollars per share)					$ 56.14
Stock-based compensation expense, including discontinued operations (in dollars)								$ 0
Performance stock units | Award Date, October 29, 2020
Stock-Based Compensation
Granted (in shares)				26,400
Weighted average grant-date fair value (in dollars per share)				$ 35.95
Stock-based compensation expense, including discontinued operations (in dollars)							$ 148		$ 362
Expired (in shares)	12,500	1,400
Vested (in shares)	12,500
Performance stock units | Award Date, April 27, 2021
Stock-Based Compensation
Number of target shares						86,175		86,175
Vesting period			3 years
Weighted average grant-date fair value (in dollars per share)			$ 44.13
Stock-based compensation expense, including discontinued operations (in dollars)						$ 0		$ 0
Expired (in shares)								6,550
Maximum number of achievable performance stock units						172,350		172,350
Performance stock units | Award Date, April 27, 2021 | Minimum
Stock-Based Compensation
Vesting (as a percent)			0%
Performance stock units | Award Date, April 27, 2021 | Maximum
Stock-Based Compensation
Unrecognized compensation expense (in dollars)						$ 7,606		$ 7,606
Vesting (as a percent)			200%

Stock-Based Compensation - Othe

Stock-Based Compensation - Other Stock Awards (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Stock-Based Compensation
Stock-based compensation expense, including discontinued operations (in dollars)	$ 6,692		$ 12,349		$ 15,301	$ 20,951
Other stock awards
Stock-Based Compensation
Issuance of common stock awards (in shares)	12,262	16,471		1,416
Weighted average grant-date fair value (in dollars per share)	$ 3.64	$ 5.57		$ 40.85
Stock-based compensation expense, including discontinued operations (in dollars)	$ 45				$ 92	$ 58

Stock-Based Compensation - Opti

Stock-Based Compensation - Options Valuation (Details) - USD ($) $ / shares in Units, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Stock-Based Compensation
Stock-based compensation expense, including discontinued operations (in dollars)	$ 6,692	$ 12,349	$ 15,301	$ 20,951
Options granted (in shares)			0
Stock options
Stock-Based Compensation
Stock-based compensation expense, including discontinued operations (in dollars)	$ 966	$ 1,861	$ 2,096	$ 3,916
Valuation assumptions:
Expected volatility (as a percent)				58.57%
Expected term (years)				5 years 5 months 23 days
Risk-free interest rate (as a percent)				0.50%
Weighted average grant-date fair value (in dollars per share)				$ 28.26

Stock-Based Compensation - Op_2

Stock-Based Compensation - Options Activity (Details) - USD ($) $ / shares in Units, $ in Thousands	6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021
Number of shares
Outstanding at beginning of period (in shares)	1,604,226
Exercised (in shares)	(12,573)
Forfeited (in shares)	(143,116)
Outstanding at end of the period (in shares)	1,448,537
Options vested and expected to vest at end of the period (in shares)	1,448,537
Exercisable at end of period (in shares)	1,379,541
Weighted average exercise price
Outstanding at beginning of period (in dollars per share)	$ 29.90
Exercised (in dollars per share)	5.01
Forfeited (in dollars per share)	46.27
Outstanding at end of period (in dollars per share)	28.49
Options vested and expected to vest at end of period (in dollars per share)	28.49
Exercisable at end of period (in dollars per share)	$ 27.16
Weighted average remaining contractual term
Outstanding	4 years 10 months 24 days
Options vested and expected to vest at of the period	4 years 10 months 24 days
Exercisable	4 years 9 months 18 days
Additional disclosures
Intrinsic value of options exercised (in dollars)	$ 2	$ 10,601
Proceeds from stock options exercised (in dollars)	60	$ 3,082
Stock options
Additional disclosures
Unrecognized compensation cost (in dollars)	$ 2,057
Weighted average period expected to be recognized	7 months 6 days

Stock-Based Compensation - Expe

Stock-Based Compensation - Expense (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	$ 6,692	$ 12,349	$ 15,301	$ 20,951
Cost of revenue - product
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	223	337	447	596
Cost of revenue - service
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	570	898	1,471	1,748
Research and development
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	761	2,069	2,280	3,272
Sales and marketing
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	50	345	308	1,042
General and administrative
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	3,488	6,178	8,289	10,541
Discontinued operations
Stock-based compensation expense
Stock-based compensation expense, including discontinued operations (in dollars)	$ 1,600	$ 2,522	$ 2,506	$ 3,752

Stock-Based Compensation - Empl

Stock-Based Compensation - Employee Stock Purchase Plan (Details) - Employee Stock Purchase Plan	Jun. 30, 2022 shares
Stock-Based Compensation
Discount (as a percent)	15%
Number of shares reserved for issuance	480,097

Fair Value Measurements - Finan

Fair Value Measurements - Financial Instruments (Details) - 2026 Notes, Convertible Senior Subordinated Notes - USD ($) $ in Thousands	Jun. 30, 2022	Feb. 12, 2019
Fair Value Measurements
Interest rate (as a percent)	1.75%	1.75%
Face value	$ 325,000	$ 325,000
Carrying Value
Fair Value Measurements
Debt instrument	319,963
Fair Value
Fair Value Measurements
Debt instrument	$ 219,193

Commitments and Contingencies -

Commitments and Contingencies - Vendor Purchase Agreements (Details) - USD ($) $ in Thousands			1 Months Ended
	Jan. 01, 2020	Mar. 29, 2019	Oct. 31, 2021	Jun. 30, 2022	Dec. 31, 2021	Nov. 30, 2021	Nov. 01, 2021	Jun. 30, 2021
Thrifty Drug Stores, Inc.
Purchase Agreements
Purchase obligation (as a percent)		98%
Amount due as a result of prescription drug purchases				$ 1,723	$ 1,854
Data aggregation partner
Purchase Agreements
Purchase obligation period	3 years
Monthly minimum purchase obligation	$ 30
Hosting services provider, one
Purchase Agreements
Minimum purchase obligation								$ 1,272
Remaining commitment				802
Enterprise support services provider
Purchase Agreements
Purchase obligation period			3 years
Minimum purchase obligation			$ 7,050
Remaining commitment				5,159
Information technology services provider
Purchase Agreements
Minimum purchase obligation							$ 8,960
Remaining commitment				6,969
Hosting services provider, two
Purchase Agreements
Minimum purchase obligation						$ 1,598
Remaining commitment				$ 729

Segment Reporting - Revenue (De

Segment Reporting - Revenue (Details) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($) segment	Jun. 30, 2021 USD ($)
Segment Reporting
Number of operating segment | segment			2
Total revenue	$ 72,597	$ 64,297	$ 139,707	$ 123,075
Product
Segment Reporting
Total revenue	55,892	46,858	106,865	88,700
Service
Segment Reporting
Total revenue	16,705	17,439	32,842	34,375
Service - PACE solutions
Segment Reporting
Total revenue	15,853	14,347	31,188	28,266
Service - Medication safety services
Segment Reporting
Total revenue	774	3,037	1,493	5,997
Service - Software subscription and services
Segment Reporting
Total revenue	78	55	161	112
CareVention HealthCare
Segment Reporting
Total revenue	71,745	61,205	138,053	116,966
CareVention HealthCare | Product
Segment Reporting
Total revenue	55,892	46,858	106,865	88,700
CareVention HealthCare | Service
Segment Reporting
Total revenue	15,853	14,347	31,188	28,266
CareVention HealthCare | Service - PACE solutions
Segment Reporting
Total revenue	15,853	14,347	31,188	28,266
Shared Services and Other
Segment Reporting
Total revenue	852	3,092	1,654	6,109
Shared Services and Other | Service
Segment Reporting
Total revenue	852	3,092	1,654	6,109
Shared Services and Other | Service - Medication safety services
Segment Reporting
Total revenue	774	3,037	1,493	5,997
Shared Services and Other | Service - Software subscription and services
Segment Reporting
Total revenue	$ 78	$ 55	$ 161	$ 112

Segment Reporting - EBITDA (Det

Segment Reporting - EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Segment Reporting
Adjusted EBITDA (loss) from continuing operations	$ 2,057	$ 3,263	$ 3,139	$ 4,846
Shared Services and Others
Segment Reporting
Adjusted EBITDA (loss) from continuing operations	(11,339)	(10,796)	(22,341)	(22,123)
CareVention HealthCare | Operating Segments
Segment Reporting
Adjusted EBITDA (loss) from continuing operations	$ 13,396	$ 14,059	$ 25,480	$ 26,969

Segment Reporting - Reconciliat

Segment Reporting - Reconciliation of Net Loss to Adjusted EBITDA (Details) - USD ($) $ in Thousands	3 Months Ended				6 Months Ended
	Jun. 30, 2022	Mar. 31, 2022	Jun. 30, 2021	Mar. 31, 2021	Jun. 30, 2022	Jun. 30, 2021
Reconciliation of Net Loss to Adjusted EBITDA from Continuing Operations
Net loss	$ (49,610)	$ (28,193)	$ (21,081)	$ (19,492)	$ (77,803)	$ (40,573)
Interest expense, net	2,444		2,182		4,713	4,729
Income tax expense	159		81		375	202
Depreciation and amortization	5,489		4,980		11,231	9,781
Impairment charges					4,062
Business optimization expenses					787
Severance costs			162		575	162
Executive transition	150				150
Divestiture-related expense	1,414				1,534
Acquisition-related expense			99			217
Stock- based compensation expense	5,092		9,827		12,795	17,199
Loss from discontinued operations	36,919		7,013		44,720	13,129
Adjusted EBITDA (loss) from continuing operations	2,057		3,263		3,139	4,846
Adjusted EBITDA from discontinued operations	1,117		2,700		2,557	4,716
Total Adjusted EBITDA	$ 3,174		$ 5,963		$ 5,696	$ 9,562

Segment Reporting - Reconcili_2

Segment Reporting - Reconciliation of Net Loss to Adjusted EBITDA, Discontinued Operations (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations
Net loss from discontinued operations, net of tax	$ (36,919)	$ (7,013)	$ (44,720)	$ (13,129)
Adjusted EBITDA from discontinued operations	1,117	2,700	2,557	4,716
DoseMe, SinfonaRx and PrescribeWellness businesses | Discontinued Operations, Held-for-sale
Reconciliation of Net Loss from Discontinued Operations, net of tax to Adjusted EBITDA from Discontinued Operations
Net loss from discontinued operations, net of tax	(36,919)	(7,013)	(44,720)	(13,129)
Income tax (benefit) expense	(686)	52	(568)	130
Depreciation and amortization		6,639	7,331	13,463
Impairment charges	35,608		36,448
Settlement	1,448	500	1,448	500
Divestiture-related expense	66		112
Stock-based compensation expense	1,600	2,522	2,506	3,752
Adjusted EBITDA from discontinued operations	$ 1,117	$ 2,700	$ 2,557	$ 4,716

Related Party Transactions (Det

Related Party Transactions (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2022	Jun. 30, 2021	Jun. 30, 2022	Jun. 30, 2021	Dec. 31, 2021
Related Party Transactions
Convertible senior subordinated notes held by a significant stockholder	$ 88,337		$ 88,337
Pharmacy services and PACE solutions services
Related Party Transactions
Revenue from related party	1,888	$ 1,696	3,647	$ 3,155
Pharmacy services and PACE solutions services | Accounts receivable, net
Related Party Transactions
Accounts receivable from related parties	$ 147		$ 147		$ 67

Subsequent Events (Details)

Subsequent Events (Details) - Subsequent Event. $ in Thousands	Aug. 01, 2022 USD ($)	Jul. 25, 2022
Subsequent Events
Repayment of line of credit	$ 57,400
Dividend declared in preferred share purchase rights per common share outstanding		1
PrescribeWellness business | Discontinued Operations, Disposed of by Sale
Subsequent Events
Consideration received	$ 125,000